US11033606B2 - Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) - Google Patents
Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) Download PDFInfo
- Publication number
- US11033606B2 US11033606B2 US14/113,757 US201214113757A US11033606B2 US 11033606 B2 US11033606 B2 US 11033606B2 US 201214113757 A US201214113757 A US 201214113757A US 11033606 B2 US11033606 B2 US 11033606B2
- Authority
- US
- United States
- Prior art keywords
- aflibercept
- administered
- dosage
- irinotecan
- fluorouracil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 229960002833 aflibercept Drugs 0.000 title claims abstract description 121
- 108010081667 aflibercept Proteins 0.000 title claims abstract description 121
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title claims abstract description 88
- 229960002949 fluorouracil Drugs 0.000 title claims abstract description 88
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 title claims abstract description 39
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 title claims abstract description 39
- 235000008191 folinic acid Nutrition 0.000 title claims abstract description 39
- 239000011672 folinic acid Substances 0.000 title claims abstract description 39
- 229960001691 leucovorin Drugs 0.000 title claims abstract description 39
- 229960004768 irinotecan Drugs 0.000 title claims description 44
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title claims description 44
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 title abstract description 22
- 239000000203 mixture Substances 0.000 title description 6
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 45
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims description 47
- 230000004083 survival effect Effects 0.000 claims description 39
- 230000004044 response Effects 0.000 claims description 16
- 238000001802 infusion Methods 0.000 claims description 14
- 229960000397 bevacizumab Drugs 0.000 claims description 13
- 238000002512 chemotherapy Methods 0.000 claims description 11
- 238000001959 radiotherapy Methods 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 7
- 229960001756 oxaliplatin Drugs 0.000 claims description 7
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 7
- 230000001394 metastastic effect Effects 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 238000011282 treatment Methods 0.000 abstract description 59
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 6
- 229940068196 placebo Drugs 0.000 description 61
- 239000000902 placebo Substances 0.000 description 61
- 238000004458 analytical method Methods 0.000 description 22
- 230000003993 interaction Effects 0.000 description 14
- 238000001990 intravenous administration Methods 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 11
- 206010027476 Metastases Diseases 0.000 description 10
- 230000034994 death Effects 0.000 description 10
- 231100000517 death Toxicity 0.000 description 10
- 238000013517 stratification Methods 0.000 description 10
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 230000006872 improvement Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 230000002411 adverse Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011319 anticancer therapy Methods 0.000 description 5
- 238000011394 anticancer treatment Methods 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000005022 packaging material Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000011519 second-line treatment Methods 0.000 description 4
- 101100129500 Caenorhabditis elegans max-2 gene Proteins 0.000 description 3
- 229940124650 anti-cancer therapies Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000001325 log-rank test Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 102100028735 Dachshund homolog 1 Human genes 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000915055 Homo sapiens Dachshund homolog 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/178—Lectin superfamily, e.g. selectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to combinations of aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan which are therapeutically useful in the treatment of Colorectal Cancer (CRC) and in particular metastatic Colorectal Cancer (CRC).
- CRC Colorectal Cancer
- CRC metastatic Colorectal Cancer
- Colorectal cancers are among the most frequent tumor types in the western countries, second to breast in women and third to lung and prostate in males.
- the end prognosis is dependent upon the extent of the disease.
- the five year survival rate in early localized stage of about 90%, decreased to approximately 60-65% after spread to adjacent organ(s) or lymph nodes and is of less than 10% after spread to distant sites.
- 5-Fluorouracil has remained the mainstay of the chemotherapy in colorectal cancer.
- 5-FU 5-Fluorouracil
- the bimonthly regimen (LV5FU2) of 5-FU given as bolus/infusion over 2 days has been shown to be superior to the monthly 5 day bolus regimen (Mayo regimen) in terms of response rate (RR) (32.6% vs 14.4%), in terms of progression free survival (PFS) (27.6 vs 22.0 weeks), and safety (de Gramont et al, Journal of Clinical Oncology 1997; 15(2):808-815).
- Aflibercept is synthesized as a fusion protein comprising the signal sequence of VEGFR1 fused to the D2 Ig domain of the VEGFR1 receptor, itself fused to the D3 Ig domain of the VEGFR2 receptor, in turn fused to the Fc domain of IgGlAflibercept is also referred to as VEGFR1R2-Fc.DELTA.C1 or Flt1D2.Flk1D3.Fc.DELTA.C1.
- amino acid sequence (SEQ ID No 1) of Aflibercept is illustrated in FIG. 1 and is also shown inter alia in FIG. 24) of patent application WO 00/75319.
- 5-fluorouracil is a drug that is a pyrimidine analog which is used in the treatment of cancer. It is a suicide inhibitor and works through irreversible inhibition of thymidylate synthase. It belongs to the family of drugs called antimetabolites.
- Folinic acid or leucovorin is an adjuvant to cancer chemotherapy used in combination with 5-fluorouracil.
- Irinotecan is a drug used for the treatment of cancer.
- Irinotecan is a topoisomerase 1 inhibitor, which prevents DNA from unwinding.
- FOLFIRI is the combination of folinic acid, 5-fluorouracil (5-FU) and irinotecan and will be used throughout the document.
- aflibercept was administered IV in combination with irinotecan (180 mg/m 2 on day 1), leucovorin (200 mg/m 2 on day 1 and day 2), and 5-FU (bolus/infusional 400/600 mg/m 2 on day 1 and day 2), every 2 weeks in patients with advanced solid malignancies.
- the invention relates to methods, compositions and articles as disclosed herein.
- the invention provides for a method of treating Colorectal Cancer (CRC) or Colorectal Cancer (CRC) symptom in a patient in need thereof, said method comprising administering to said patient therapeutically effective amounts of aflibercept and FOLFIRI. This method is safe and effective.
- the invention provides for a method of increasing Overall Survival (OS) in a patient afflicted with CRC, said method comprising administering to said patient therapeutically effective amounts of aflibercept and FOLFIRI.
- OS Overall Survival
- the invention provides a method of increasing Overall Response Rate (ORR) in a patient afflicted with CRC, said method comprising administering to said patient therapeutically effective amounts of aflibercept and FOLFIRI.
- ORR Overall Response Rate
- the invention provides a method of increasing Progression Free Survival (PFS) in a patient afflicted with CRC, said method comprising administering to said patient therapeutically effective amounts of aflibercept and FOLFIRI.
- PFS Progression Free Survival
- the invention provides a method according to any one of the first to fourth aspects wherein said patient has already been treated for the CRC or CRC symptom (second-line treatment).
- CRC is a Metastatic Colorectal Cancer.
- the invention provides for a method according to any one of the first to fourth aspects or the first feature wherein said patient has previously been treated with chemotherapy, radiotherapy or surgery. In an embodiment said patient has failed chemotherapy, radiotherapy or surgery.
- the invention provides a method according to any one of the first to fourth aspects or the first feature wherein said patient has previously been treated with therapy based on oxaliplatin or on bevacizumab.
- said patient has failed therapy based on oxaliplatin or on bevacizumab.
- the invention provides a method wherein folinic acid at a dosage comprised between about 200 mg/m 2 and about 600 mg/m 2 , 5-fluorouracil (5-FU) at a dosage comprised between about 2000 mg/m 2 and about 4000 mg/m 2 , irinotecan at a dosage comprised between about 100 mg/m 2 and about 300 mg/m 2 and aflibercept at a dosage comprised between about 1 mg/kg and about 10 mg/kg are administered to patient.
- 5-fluorouracil 5-FU
- the dosage of folinic acid indicated should be understood as the dosage of the racemate of folinic acid, i.e. comprising the D and L forms. Should only the L form be used the dosage should be half of the dosage indicated for the racemate.
- a dosage of folinic acid of about 200 mg/m 2 as indicated in the present application corresponds to about 200 mg/m 2 of racemate and about 100 mg/m 2 of L form.
- the invention provides a method wherein folinic acid at a dosage of about 400 mg/m 2 , 5-fluorouracil (5-FU) at a dosage of about 2800 mg/m 2 , irinotecan at a dosage of about 180 mg/m 2 and aflibercept at a dosage of about 4 mg/kg are administered to patient.
- the invention provides a method wherein said patient receives intravenous folinic acid at a dosage comprised of about 400 mg/m 2 , intravenous 5-fluorouracil (5-FU) at a dosage of about 2800 mg/m 2 , intravenous irinotecan at a dosage comprised of about 180 mg/m 2 and intravenous aflibercept at a dosage of about 4 mg/kg every two weeks.
- intravenous folinic acid at a dosage comprised of about 400 mg/m 2
- intravenous 5-fluorouracil (5-FU) at a dosage of about 2800 mg/m 2
- intravenous irinotecan at a dosage comprised of about 180 mg/m 2
- intravenous aflibercept at a dosage of about 4 mg/kg every two weeks.
- the invention provides a method wherein said patient receives intravenous folinic acid, intravenous 5-fluorouracil (5-FU), intravenous irinotecan and intravenous aflibercept every two weeks for a period comprised between about 9 and about 18 weeks.
- the invention provides a method wherein said patient receives intravenous folinic acid immediately after aflibercept administration.
- the invention provides a method wherein said patient receives intravenous irinotecan immediately after aflibercept administration.
- the invention provides a method wherein said patient receives intravenous irinotecan immediately after aflibercept administration over almost 90 minutes.
- the invention provides a method wherein said patient receives intravenous 5-fluorouracil (5-FU) immediately after aflibercept administration.
- the invention provides a method wherein said patient receives a first quantity of intravenous 5-fluorouracil (5-FU) immediately after aflibercept administration and a second quantity in continuous infusion.
- 5-FU intravenous 5-fluorouracil
- the invention provides a method wherein said patient receives about 400 mg/m 2 of intravenous 5-fluorouracil (5-FU) over about 2 to 4 minutes after aflibercept administration and 2400 mg/m 2 over about 46 hours after aflibercept administration in continuous infusion.
- 5-FU intravenous 5-fluorouracil
- the invention features a composition comprising therapeutically effective amounts of aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan for treating patients with CRC for simultaneous administration.
- aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan for treating patients with CRC for simultaneous administration.
- the invention features a composition comprising therapeutically effective amounts of aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan for treating patients with CRC for sequential administration.
- aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan for treating patients with CRC for sequential administration.
- the invention features a composition comprising therapeutically effective amounts of aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan for treating patients with CRC for administration that is spaced out over a period of time so as to obtain the maximum efficacy of the combination.
- the invention features a composition comprising therapeutically effective amounts of aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan and comprising a pharmaceutically acceptable carrier for treating patients with CRC.
- the patient has liver metastases.
- the invention features an article of manufacture comprising:
- the label or package insert contained within said packaging material indicates that aflibercept in combination with FOLFIRI improves Overall Survival (OS).
- the label or package insert contained within said packaging material indicates that aflibercept in combination with FOLFIRI improves Progression Free Survival (PFS).
- the label or package insert contained within said packaging material indicates that aflibercept in combination with FOLFIRI improves Overall Response Rate (ORR).
- the invention features a kit for treating patients with CRC comprising:
- the invention features a kit comprising in separate containers pharmaceutical compositions for combined use in treating CRC in a patient which comprises (1) a pharmaceutical composition comprising aflibercept, (2) a pharmaceutical composition comprising folinic acid, (3) a pharmaceutical composition comprising 5-fluorouracil (5-FU) and (4) a pharmaceutical composition comprising irinotecan.
- the aflibercept can be formulated as described in WO2006/104852.
- the man skilled in the art may refer in particular to WO2006/104852 or to WO 00/75319 to carry out the present invention.
- FIG. 1 Aflibercept amino acid sequence (SEQ ID NO:1)
- FIG. 2 Overall survival (months)—Kaplan-Meier curves by treatment group—ITT population
- FIG. 3 Overall survival (months)—Subgroup analyses (forest plot)—By stratification factors as per IVRS—ITT population
- FIG. 4 Overall survival (months)—Subgroup analyses (forest plot)—By patient demographics—ITT population
- FIG. 5 Overall survival (months)—Subgroup analyses (forest plot)—By baseline characteristics—ITT population
- FIG. 6 PFS based on tumor assessment by the IRC (months)—Subgroup analysis (forest plot)—By stratification factors as per IVRS—ITT population
- EFC10262 (VELOUR)/A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan/5-FU Combination (FOLFIRI) after failure of an oxaliplatin based regimen
- EFC10262 was designed as a randomized, double-blind, multi-centre study comparing aflibercept at 4 mg/kg to placebo, in combination with Irinotecan and 5 Fluorouracil combination (FOLFIRI) given intravenously every 2 weeks as second line treatment for patients with metastatic colorectal cancer (MCRC) after failure of an oxaliplatin based regimen. Each randomized patient was to be treated until disease progression, death, or unacceptable toxicity.
- FOLFIRI Fluorouracil combination
- EFC10262 The primary objective of EFC10262 was to demonstrate improvement in overall survival (OS) for aflibercept+FOLFIRI compared to placebo+FOLFIRI.
- OS overall survival
- placebo+FOLFIRI The predefined statistical significance level for this final analysis was 0.0466 after adjusting the type I error spent for the two interim analyses using the O'Brien-Fleming spending function.
- DMC Data Monitoring Committee
- Treatment assignment was stratified according to prior therapy with bevacizumab (yes or no), and ECOG performance status (PS) (0 vs 1 vs 2).
- the enrolment started in November 2007 and was completed in March 2010. A total of 1226 patients were randomized. The efficacy analysis was based on all randomized patients (Intent-to-Treat (ITT) population: 614 in the placebo arm and 612 patients in the aflibercept arm). The safety analysis was based on all treated patients (safety population: 605 and 611 patients in the placebo and aflibercept arms, respectively). Treatment arms were evenly balanced for demographics, disease characteristics and prior anti-cancer treatments, including prior exposition to bevacizumab.
- ITT Intent-to-Treat
- Arm B placebo: 4 mg/kg was administered IV over 1 hour on Day 1, every 2 weeks.
- the median overall study treatment exposure i.e. either both study drugs aflibercept/placebo and FOLFIRI, or one of them alone
- the median overall study treatment exposure was 8.0 and 9.0 cycles in the placebo and aflibercept treatment arms, respectively (Table 4).
- the median number of aflibercept/placebo infusions was 8.0 and 7.0 in the placebo and aflibercept treatment arms, respectively (Table 5).
- the median relative dose intensity was 83% with aflibercept as compared to 92% with placebo.
- the median number of irinotecan infusions was 8.0 and 9.0 in the placebo and aflibercept treatment arms, respectively (table 6).
- the median relative dose intensity was 84% in the aflibercept arm as compared to 91% in the placebo arm.
- two patients did not receive irinotecan; the dose was considered equal to 0 for the calculation of the cumulative dose, actual and relative dose intensity.
- the median number of 5-FU infusions was 8.0 and 9.0 in the placebo and aflibercept treatment arms, respectively (Table 7).
- the median relative dose intensity was 83% in the aflibercept arm as compared to 91% in the placebo arm.
- two patients did not receive 5-FU; the dose was considered equal to 0 for the calculation of the cumulative dose, actual and relative dose intensity.
- the median follow-up time at the cutoff date (7 Feb. 2011) for the ITT population was 22.28 months ( FIG. 2 and Table 8).
- the hazard ratio translates into a reduction of risk of death of 18.3% (95.34 Cl: 6.3% to 28.7%) with aflibercept compared to placebo.
- the estimated probabilities of being alive were 50.3% in placebo arm and 56.1% aflibercept arm, and 30.9% in placebo arm and 38.5% in aflibercept arm.
- Median overall survival was 13.50 months vs 12.06 months in aflibercept and placebo treatment arms, respectively.
- Sensitivity analyses and subgroup analyses showed a very consistent treatment effect confirming robustness of results on the primary endpoint.
- Treatment effect for OS was consistent across subgroups with regards to baseline characteristics at study entry.
- PFS progression free survival
- PFS Progression free survival
- Treatment effect for PFS was consistent across subgroups with regards to baseline characteristics at study entry.
- the interaction between treatment arms and the presence of liver metastasis factor, that was noted on OS, was also significant at 10% level, indicating a higher treatment effect ‘in liver metastasis only’ group (HR (99.99% Cl): 0.547 (0.313 to 0.956)) than in ‘no liver metastasis, or other metastases’ group (HR (99.99% Cl): 0.839 (0.617 to 1.143)) (quantitative interaction, p 0.0076).
- the safety profile was qualitatively consistent with that of anti VEGF treatment with enhancement of known toxicities of the background chemotherapy (such as diarrhea, stomatitis, infections, neutropenia/neutropenic complications).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
-
- a) a packaging material
- b) aflibercept, and
- c) a label or package insert contained within said packaging material indicating that aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan is effective for the treatment of CRC
-
- a) at least one compound chosen from the list consisting of aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan; and
- b) a label or package insert contained within said kit indicating that aflibercept is to be used in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) or folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) is to be used in combination with Aflibercept
-
- Irinotecan 180 mg/m2 IV infusion in 500 mL in 5% dextrose solution in water (D5W) over 90 minutes and dextro-levogyre (dl) leucovorin 400 mg/m2 IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by:
- 5-
FU 400 mg/m2 IV bolus given over 2-4 minutes, followed by: - 5-FU 2400 mg/m2 continuous IV infusion in 500 mL D5W (recommended) over 46-hours.
Results of EFC10262
Demographics and Baseline Characteristics
TABLE 1 |
Summary of patient demographics and patient |
characteristics at baseline - ITT population |
Placebo/Folfiri | Aflibercept/Folfiri | All | ||
(N = 614) | (N = 612) | (N = 1226) | ||
Gender [n(%)] | |||
Number | 614 | 612 | 1226 |
Male | 353 (57.5%) | 365 (59.6%) | 718 (58.6%) |
Female | 261 (42.5%) | 247 (40.4%) | 508 (41.4%) |
Age (Years) | |||
Number | 614 | 612 | 1226 |
Median | 61.0 | 61.0 | 61.0 |
Mean (SD) | 60.2 (10.8) | 59.5 (10.5) | 59.8 (10.7) |
Min:Max | 19:86 | 21:82 | 19:86 |
Age class [n(%)] | |||
Number | 614 | 612 | 1226 |
<65 | 376 (61.2%) | 407 (66.5%) | 783 (63.9%) |
≥65 but <75 | 199 (32.4%) | 172 (28.1%) | 371 (30.3%) |
≥75 | 39 (6.4%) | 33 (5.4%) | 72 (5.9%) |
Race [n(%)] | |||
Number | 614 | 612 | 1226 |
Caucasian/White | 523 (85.2%) | 548 (89.5%) | 1071 (87.4%) |
Black | 27 (4.4%) | 16 (2.6%) | 43 (3.5%) |
Asian/Oriental | 51 (8.3%) | 35 (5.7%) | 86 (7.0%) |
Other | 13 (2.1%) | 13 (2.1%) | 26 (2.1%) |
Region | |||
Number | 614 | 612 | 1226 |
Western Europe | 217 (35.3%) | 208 (34.0%) | 425 (34.7%) |
Eastern Europe | 136 (22.1%) | 161 (26.3%) | 297 (24.2%) |
North America | 75 (12.2%) | 63 (10.3%) | 138 (11.3%) |
South America | 56 (9.1%) | 62 (10.1%) | 118 (9.6%) |
Other countries | 130 (21.2%) | 118 (19.3%) | 248 (20.2%) |
Note: | |||
Other countries = Australia, New Zeland, South Africa and Korea |
TABLE 2 |
Disease characteristics at initial diagnosis - ITT population |
Aflibercept/ | ||||
Placebo/Folfiri | Folfiri | All | ||
(N = 614) | (N = 612) | (N = 1226) | ||
Primary site | |||
[n(%)] | |||
Number | 614 | 612 | 1226 |
Colon | 302 | (49.2%) | 289 | (47.2%) | 591 | (48.2%) |
Recto sigmoid | 136 | (22.1%) | 123 | (20.1%) | 259 | (21.1%) |
Rectum | 174 | (28.3%) | 197 | (32.2%) | 371 | (30.3%) |
Other | 2 | (0.3%) | 3 | (0.5%) | 5 | (0.4%) |
cea & ck20 postive - | 1 | (0.2%) | 0 | 1 | (<0.1%) |
presumed colorectal | |||||
primary |
Appendix | 0 | 1 | (0.2%) | 1 | (<0.1%) |
Colon plus appendix | 0 | 1 | (0.2%) | 1 | (<0.1%) |
Presumed colorectal, | 0 | 1 | (0.2%) | 1 | (<0.1%) |
cea positive and | |||||
history of colon | |||||
cancer >20 years ago |
Synchronous primary, | 1 | (0.2%) | 0 | 1 | (<0.1%) |
cecum and rectum |
Histology type | |||
[n(%)] | |||
Number | 614 | 612 | 1226 |
Adenocarcinoma | 614 | (100%) | 612 | (100%) | 1226 | (100%) |
Time from 1st | |||
diagnosis to | |||
randomization | |||
(months) [n(%)]* | |||
Number | 614 | 611 | 1225 |
Mean (SD) | 20.88 | (21.10) | 20.98 | (24.08) | 20.93 | (22.62) |
Median | 13.67 | 14.62 | 14.26 |
Min:Max | 2.4:214.7 | 2.1:325.1 | 2.1:325.1 |
*If the day of initial date of diagnosis is missing, it is considered as the first day of the month |
Patient Accountability
TABLE 3 |
Summary of randomized patients by stratification |
factor (as per IVRS) - ITT population |
Placebo/Folfiri | Aflibercept/Folfiri | All | |
Stratification factors | (N = 614) | (N = 612) | (N = 1226) |
ECOG PS [n(%)] | |||
0 | 350 (57.0%) | 349 (57.0%) | 699 (57.0%) |
1 | 250 (40.7%) | 250 (40.8%) | 500 (40.8%) |
2 | 14 (2.3%) | 13 (2.1%) | 27 (2.2%) |
Prior Bevacizumab | |||
[n(%)] | |||
Yes | 187 (30.5%) | 186 (30.4%) | 373 (30.4%) |
No | 427 (69.5%) | 426 (69.6%) | 853 (69.6%) |
Note: | |||
ECOG: Eastern Cooperative Oncology Group, PS: Performance Status, IVRS: Interactive Voice response System |
Dosage and Duration
TABLE 4 |
Summary of overall study treatment exposure - Safety population |
Number of cycles | Placebo/Folfiri | Aflibercept/Folfiri | ||
received by patient | (N = 605) | (N = 611) | ||
Sum | 6127 | 6358 | ||
Mean (SD) | 10.1 (8.1) | 10.4 (7.6) | ||
Median | 8.0 | 9.0 | ||
Min:Max | 1:67 | 1:50 | ||
SD: standard deviation |
TABLE 5 |
Exposure to Aflibercept/Placebo - Safety population |
Placebo/Folfiri | Aflibercept/Folfiri | ||||
(N = 605) | (N = 611) | ||||
Number of cycles | ||
received by patient | ||
Sum | 6035 | 5632 |
Mean (SD) | 10.0 | (8.0) | 9.2 | (7.2) |
Median | 8.0 | 7.0 |
Min:Max | 1:67 | 1:35 |
1 | 24 | (4.0%) | 43 | (7.0%) |
2 | 32 | (5.3%) | 52 | (8.5%) |
3 | 85 | (14.0%) | 70 | (11.5%) |
4 | 31 | (5.1%) | 45 | (7.4%) |
5 | 32 | (5.3%) | 43 | (7.0%) |
6 | 45 | (7.4%) | 29 | (4.7%) |
7 | 29 | (4.8%) | 28 | (4.6%) |
8 | 34 | (5.6%) | 29 | (4.7%) |
9 | 45 | (7.4%) | 29 | (4.7%) |
10 | 21 | (3.5%) | 28 | (4.6%) |
11-15 | 112 | (18.5%) | 94 | (15.4%) |
16-20 | 57 | (9.4%) | 68 | (11.1%) |
21-25 | 28 | (4.6%) | 34 | (5.6%) |
>25 | 30 | (5.0%) | 19 | (3.1%) |
Duration of exposure to | ||||
aflibercept/placebo (weeks) |
Number | 605 | 611 |
Mean (SD) | 22.3 | (17.5) | 21.7 | (16.7) |
Median | 18.0 | 17.9 |
Min:Max | 2:135 | 2:85 |
Total cumulative | ||||
dose received (mg/kg) |
Number | 605 | 611 |
Mean (SD) | 39.63 | (31.65) | 35.69 | (27.96) |
Median | 32.00 | 28.00 |
Min:Max | 0.6:266.4 | 3.8:140.0 |
Actual dose | ||||
intensity (mg/kg/week) |
Number | 605 | 611 |
Mean (SD) | 1.78 | (0.25) | 1.55 | (0.44) |
Median | 1.84 | 1.66 |
Min:Max | 0.3:2.1 | 0.1:2.1 |
Relative dose intensity |
Number | 605 | 611 |
Mean (SD) | 0.89 | (0.12) | 0.78 | (0.22) |
Median | 0.92 | 0.83 |
Min:Max | 0.2:1.1 | 0.1:1.1 |
Number of cycles received: Number of cycles with at least one dose infusion of aflibercept/placebo. |
TABLE 6 |
Exposure to irinotecan- Safety population |
Placebo/Folfiri | Aflibercept/Folfiri | ||
(N = 605) | (N = 611) | ||
Number of cycles | ||
received by patient |
Sum | 5992 | 6157 |
Mean (SD) | 9.9 | (7.8) | 10.1 | (7.4) |
Median | 8.0 | 9.0 |
Min:Max | 1:67 | 1:50 |
1 | 23 | (3.8%) | 34 | (5.6%) |
2 | 29 | (4.8%) | 39 | (6.4%) |
3 | 87 | (14.4%) | 64 | (10.5%) |
4 | 33 | (5.5%) | 36 | (5.9%) |
5 | 29 | (4.8%) | 37 | (6.1%) |
6 | 48 | (7.9%) | 31 | (5.1%) |
7 | 27 | (4.5%) | 27 | (4.4%) |
8 | 32 | (5.3%) | 29 | (4.8%) |
9 | 47 | (7.8%) | 29 | (4.8%) |
10 | 21 | (3.5%) | 38 | (6.2%) |
11-15 | 114 | (18.9%) | 111 | (18.2%) |
16-20 | 58 | (9.6%) | 78 | (12.8%) |
21-25 | 31 | (5.1%) | 35 | (5.7%) |
>25 | 25 | (4.1%) | 22 | (3.6%) |
Duration of exposure | ||||
to irinotecan (weeks) |
Number | 604 | 610 |
Mean (SD) | 22.2 | (17.2) | 23.5 | (16.9) |
Median | 18.1 | 21.0 |
Min:Max | 2:135 | 2:105 |
Total cumulative | ||||
dose received (mg/m2) |
Number | 605 | 611 |
Mean (SD) | 1736.30 | (1355.52) | 1730.37 | (1273.76) |
Median | 1440.00 | 1472.50 |
Min:Max | 0.0:11948.1 | 0.0:9046.1 |
Actual dose | ||||
intensity (mg/m2/week) |
Number | 605 | 611 |
Mean (SD) | 78.82 | (11.74) | 73.59 | (13.68) |
Median | 82.08 | 75.60 |
Min:Max | 0.0:95.0 | 0.0:95.0 |
Relative dose | ||||
intensity |
Number | 605 | 611 |
Mean (SD) | 0.88 | (0.13) | 0.82 | (0.15) |
Median | 0.91 | 0.84 |
Min:Max | 0.0:1.1 | 0.0:1.1 |
Number of cycles received: Number of cycles with at least one dose infusion of irinotecan. |
TABLE 7 |
Exposure to 5-FU - Safety population |
Placebo/Folfiri | Aflibercept/Folfiri | ||
(N = 605) | (N = 611) | ||
Number of cycles | ||
received by patient |
Sum | 6030 | 6155 |
Mean (SD) | 10.0 | (7.9) | 10.1 | (7.4) |
Median | 8.0 | 9.0 |
Min:Max | 1:67 | 1:50 |
1 | 22 | (3.6%) | 35 | (5.7%) |
2 | 28 | (4.6%) | 39 | (6.4%) |
3 | 88 | (14.6%) | 63 | (10.3%) |
4 | 33 | (5.5%) | 35 | (5.7%) |
5 | 28 | (4.6%) | 37 | (6.1%) |
6 | 48 | (8.0%) | 32 | (5.2%) |
7 | 27 | (4.5%) | 28 | (4.6%) |
8 | 33 | (5.5%) | 28 | (4.6%) |
9 | 47 | (7.8%) | 29 | (4.7%) |
10 | 20 | (3.3%) | 39 | (6.4%) |
11-15 | 114 | (18.9%) | 113 | (18.5%) |
16-20 | 59 | (9.8%) | 77 | (12.6%) |
21-25 | 28 | (4.6%) | 35 | (5.7%) |
>25 | 28 | (4.6%) | 21 | (3.4%) |
Duration of | ||||
exposure to 5-FU | ||||
(weeks) |
Number | 603 | 611 |
Mean (SD) | 22.4 | (17.5) | 23.5 | (16.9) |
Median | 18.1 | 21.0 |
Min:Max | 2:135 | 2:105 |
Total cumulative | ||||
dose received | ||||
(mg/m2) |
Number | 605 | 611 |
Mean (SD) | 27142.02 | (21341.89) | 26644.81 | (19245.24) |
Median | 22400.00 | 22702.44 |
Min:Max | 0.0:185874.8 | 409.0:126701.4 |
Actual dose | ||||
intensity | ||||
(mg/m2/week) |
Number | 605 | 611 |
Mean (SD) | 1227.42 | (190.51) | 1140.36 | (214.35) |
Median | 1276.38 | 1165.56 |
Min:Max | 0.0:1477.3 | 177.0:1491.3 |
Relative dose | ||||
intensity |
Number | 605 | 611 |
Mean (SD) | 0.88 | (0.14) | 0.81 | (0.15) |
Median | 0.91 | 0.83 |
Min:Max | 0.0:1.1 | 0.1:1.1 |
Number of cycles received: Number of cycles with at least one dose infusion of 5-FU. |
Results of EFC10262
TABLE 8 |
Overall survival (months) - Kaplan-Meier survival estimates by |
treatment group- Primary analysis- Stratified according to stratification |
factors at randomization (IVRS) - ITT population |
Placebo/Folfiri | Aflibercept/Folfiri | |
Time to Event or Censoring | (N = 614) | (N = 612) |
Overall | ||
Number of death events, | 460/614 (74.9%) | 403/612 (65.8%) |
n/N (%) | ||
Median overall survival | 12.06 (11.072 | 13.50 (12.517 |
(95.34% CI) (months) | to 13.109) | to 14.949) |
Number of patients at risk | ||
3 months | 573 | 566 |
6 months | 485 | 498 |
9 months | 401 | 416 |
12 months | 286 | 311 |
18 months | 131 | 148 |
24 months | 51 | 75 |
Survival probability | ||
(95.34% CI) | ||
3 months | 0.935 (0.915 | 0.931 (0.911 |
to 0.955) | to 0.951) | |
6 months | 0.791 (0.759 | 0.819 (0.788 |
to 0.824) | to 0.850) | |
9 months | 0.654 (0.616 | 0.687 (0.650 |
to 0.692) | to 0.725) | |
12 months | 0.503 (0.462 | 0.561 (0.521 |
to 0.543) | to 0.602) | |
18 months | 0.309 (0.269 | 0.385 (0.343 |
to 0.348) | to 0.427) | |
24 months | 0.187 (0.149 | 0.280 (0.237 |
to 0.225) | to 0.324) | |
Stratified Log-Rank | ||
test p-valuea | ||
vs Placebo/Folfiri | — | 0.0032 |
Stratified Hazard ratio | ||
(95.34% CI)a | ||
vs Placebo/Folfiri | — | 0.817 (0.713 |
to 0.937) | ||
Cutoff date = 7 FEB. 2011 | ||
Median follow-up time = 22.28 in months | ||
aStratified on ECOG Performance Status (0 vs 1 vs 2) and Prior Bevacizumab (yes vs no) according to IVRS. Significance threshold is set to 0.0466 using the O'Brien-Fleming alpha spending function. |
Subgroup Analyses of Overall Survival (OS)
TABLE 9 |
Overall survival (months) - Summary of subgroup analyses - |
By stratification factors as per IVRS - ITT population |
Placebo/Folfiri | Aflibercept/Folfiri | Hazard Ratio | |||
Median (Months) | Median (Months) | (95.34% CI) vs | P-value for | ||
(95.34% CI) | (95.34% CI) | Placebo/Folfiri | interaction a | ||
All patients | 12.1 (11.07 | 13.5 (12.52 | 0.817 (0.713 | |
to 13.11) | to 14.95) | to 0.937) | ||
Prior | ||||
bevacizumab | ||||
No | 12.4 (11.17 | 13.9 (12.71 | 0.788 (0.669 | 0.7231 |
to 13.54) | to 15.64) | to 0.927) | ||
Yes | 11.7 (9.82 | 12.5 (10.78 | 0.862 (0.673 | |
to 13.77) | to 15.51) | to 1.104) | ||
|
||||
0 | 14.1 (12.88 | 16.9 (14.78 | 0.768 (0.635 | 0.5668 |
to 16.62) | to 18.79) | to 0.928) | ||
1 | 10.1 (9.20 | 10.7 (9.36 | 0.869 (0.71 | |
to 11.53) | to 12.35) | to 1.063) | ||
2 | 4.4 (1.97 | 2.8 (0.92 | 0.978 (0.43 | |
to 10.02) | to 9.82) | to 2.221) | ||
Cutoff date = 7 FEB. 2011 | ||||
Median follow-up time = 22.28 in months | ||||
a Interaction test from the Cox proportional hazard model including the factor, treatment effect and the treatment by factor interaction |
TABLE 10 |
Overall survival (months) - Summary of subgroup analyses - |
By baseline characteristics - ITT population |
Placebo/Folfiri | Aflibercept/Folfiri | Hazard Ratio | |||
Median (Months) | Median (Months) | (95.34% CI) vs | P-value for | ||
(95.34% CI) | (95.34% CI) | Placebo/Folfiri | interactiona | ||
All patients | 12.1 (11.07 | 13.5 (12.52 | 0.817 (0.713 | |
to 13.11) | to 14.95) | to 0.937) | ||
Prior | ||||
hypertension | ||||
No | 11.7 (10.41 | 12.7 (11.17 | 0.883 (0.74 | 0.1309 |
to 13.11) | to 14.39) | to 1.054) | ||
Yes | 12.7 (10.78 | 15.5 (12.91 | 0.714 (0.577 | |
to 14.00) | to 18.56) | to 0.884) | ||
Number of | ||||
metastatic organs | ||||
involved | ||||
>1 | 10.5 (9.72 | 12.1 (10.71 | 0.825 (0.692 | 0.6992 |
to 12.06) | to 13.11) | to 0.982) | ||
<=1 | 13.7 (12.29 | 16.0 (14.42 | 0.767 (0.618 | |
to 16.30) | to 20.86) | to 0.953) | ||
Liver Metastasis | ||||
only | ||||
No | 12.3 (11.07 | 13.2 (12.06 | 0.868 (0.742 | 0.0899 |
to 13.73) | to 15.28) | to 1.015) | ||
Yes | 11.4 (9.86 | 14.4 (12.68 | 0.649 (0.492 | |
to 12.88) | to 18.04) | to 0.855) | ||
Location of | ||||
primary tumor | ||||
Colon | 10.6 (9.66 | 12.9 (11.50 | 0.739 (0.607 | 0.1421 |
to 12.06) | to 16.16) | to 0.899) | ||
Recto | 14.1 (12.71 | 14.3 (12.35 | 1.039 (0.772 | |
sigmoid/Other | to 17.08) | to 16.39) | to 1.4) | |
Rectum | 12.6 (10.35 | 13.5 (11.93 | 0.806 (0.629 | |
to 14.55) | to 15.87) | to 1.031) | ||
Median follow-up time = 22.28 in months | ||||
aInteraction test from the Cox proportional hazard model including the factor, treatment effect and the treatment by factor interaction |
TABLE 11 |
PFS based on tumor assessment by the IRC (months) - Kaplan-Meier |
survival estimates by treatment group - Stratified according to |
stratification factors at randomization (IVRS) - ITT population |
Placebo/Folfiri | Aflibercept/Folfiri | |
Time to Event or Censoring | (N = 614) | (N = 612) |
Overall | ||
Number of events, n/N(%) | 454/614 (73.9%) | 393/612 (64.2%) |
Median PFS (99.99% CI) | 4.67 (4.074 | 6.90 (5.881 |
(months) | to 5.552) | to 7.852) |
Number at risk | ||
3 months | 355 | 420 |
6 months | 171 | 247 |
9 months | 94 | 99 |
12 months | 46 | 43 |
18 months | 9 | 7 |
Probability of surviving | ||
(99.99% CI) | ||
3 months | 0.664 (0.587 | 0.793 (0.727 |
to 0.741) | to 0.859) | |
6 months | 0.390 (0.306 | 0.573 (0.488 |
to 0.475) | to 0.659) | |
9 months | 0.254 (0.174 | 0.313 (0.222 |
to 0.334) | to 0.404) | |
12 months | 0.146 (0.076 | 0.166 (0.085 |
to 0.216) | to 0.246) | |
18 months | 0.043 (0.000 | 0.051 (0.000 |
to 0.091) | to 0.108) | |
Stratified Log-Rank | ||
test p-valuea | ||
vs Placebo/Folfiri | — | 0.00007 |
Stratified Hazard | ||
ratio (99.99% CI)a | ||
vs Placebo/Folfiri | — | 0.758 (0.578 |
to 0.995) | ||
Cutoff date = 06 MAY 2010 | ||
aStratified on ECOG Performance Status (0 vs 1 vs 2) and Prior Bevacizumab (yes vs no) according to IVRS | ||
Significance threshold is set to 0.0001. |
Subgroup Analyses of Progression Free Survival
TABLE 12 |
PFS based on tumor assessment by the IRC (months) - Summary of subgroup |
analyses - By stratification factors as per IVRS - ITT population |
Placebo/Folfiri | Aflibercept/Folfiri | Hazard Ratio | |||
Median (Months) | Median (Months) | (99.99% CI) vs | P-value for | ||
(99.99% CI) | (99.99% CI) | Placebo/Folfiri | interactiona | ||
All patients | 4.7 (4.07 | 6.9 (5.88 | 0.758 (0.578 | |
to 5.55) | to 7.85) | to 0.995) | ||
Prior | ||||
bevacizumab | ||||
No | 5.4 (4.17 | 6.9 (5.82 | 0.797 (0.58 | 0.6954 |
to 6.70) | to 8.15) | to 1.096) | ||
Yes | 3.9 (2.86 | 6.7 (4.76 | 0.661 (0.399 | |
to 5.42) | to 8.74) | to 1.095) | ||
|
||||
0 | 5.4 (4.24 | 7.2 (6.37 | 0.761 (0.529 | 0.1958 |
to 6.77) | to 8.87) | to 1.094) | ||
1 | 4.1 (2.83 | 5.6 (4.60 | 0.749 (0.494 | |
to 5.55) | to 7.46) | to 1.135) | ||
2 | 2.0 (1.18 | 2.7 (0.53 | 0.618 (0.11 | |
to 5.75) | to 12.88) | to 3.476) | ||
Cutoff date = 06 MAY 2010 | ||||
aInteraction test from the Cox proportional hazard model including the factor, treatment effect and the treatment by factor interaction |
TABLE 13 |
Summary of overall objective response rate by IRC - |
Evaluable patient population for response rate |
Placebo/Folfiri | Aflibercept/Folfiri | ||||
(N = 530) | (N = 531) | ||||
Best Overall | |||
Response [n(%)] | |||
Complete response | 2 | (0.4%) | 0 |
Partial response | 57 | (10.8%) | 105 | (19.8%) |
Stable disease | 344 | (64.9%) | 350 | (65.9%) |
Progressive disease | 114 | (21.5%) | 55 | (10.4%) |
Not evaluable | 13 | (2.5%) | 21 | (4.0%) |
Overall Response | ||||
Responders (Complete | 59 | (11.1%) | 105 | (19.8%) |
response or | ||||
Partial response) |
95% CIa | 8.5% to 13.8% | 16.4% to 23.2% |
Stratified Cochran-Mantel- | ||
Haenszel test p-valueb | ||
Vs Placebo/Folfiri | — | 0.0001 |
aestimated by Normal approximation | ||
bStratified on ECOG Performance Status (0 |
TABLE 14 |
Summary of first further anti-cancer therapies - ITT population |
Placebo/Folfiri | Aflibercept/Folfiri | ||
(N = 614) | (N = 612) | ||
At least one further | ||||
therapy [n(%)] | ||||
Yes | 366 | (59.6%) | 364 | (59.5%) |
No | 248 | (40.4%) | 248 | (40.5%) |
Type of first further | ||||
therapy [n(%)] | ||||
Systemic anti-cancer treatment | 303/366 | (82.8%) | 296/364 | (81.3%) |
Radiotherapy | 43/366 | (11.7%) | 34/364 | (9.3%) |
Surgery | 20/366 | (5.5%) | 34/364 | (9.3%) |
Time from last IV to first | ||||
further systemic anti-cancer | ||||
therapy (months)a |
|
297 | 293 |
Mean (SD) | 1.87 | (1.71) | 2.37 | (2.45) |
Median | 1.35 | 1.58 |
Min:Max | 0.3:14.0 | 0.2:20.5 |
Time from last IV to first | ||||
further radiotherapy (months)a |
Number | 43 | 33 |
Mean (SD) | 3.02 | (3.86) | 3.25 | (3.38) |
Median | 1.31 | 2.07 |
Min:Max | 0.4:16.5 | 0.6:14.6 |
Time from last IV to first | ||||
further surgery (months)a |
Number | 20 | 34 |
Mean (SD) | 1.62 | (1.41) | 2.42 | (2.08) |
Median | 1.15 | 1.48 |
Min:Max | 0.4:7.2 | 0.2:8.5 |
Systemic anti-cancer therapies include chemotherapy and biologies. Only the earliest date of further therapy in each category (systemic anti-cancer treatment, radiotherapy or surgery) is kept | ||
aTime from last IV to first futher therapy is not calculated for patients randomized but not treated. |
TABLE 15 |
Summary of all further anti-cancer therapies - ITT population |
Placebo/Folfiri | Aflibercept/Folfiri | ||
(N = 614) | (N = 612) | ||
Any further therapy | 366 | (59.6%) | 364 | (59.5%) |
Surgery | 31 | (5.0%) | 47 | (7.7%) |
Radiotherapy | 81 | (13.2%) | 79 | (12.9%) |
Systemic anti-cancer treatment | 329 | (53.6%) | 329 | (53.8%) |
Biologies/Small molecules | 197 | (32.1%) | 195 | (31.9%) |
Cetuximab | 91 | (14.8%) | 108 | (17.6%) |
Bevacizumab | 75 | (12.2%) | 55 | (9.0%) |
Panitumumab | 52 | (8.5%) | 52 | (8.5%) |
Other | 14 | (2.3%) | 21 | (3.4%) |
Chemotherapy | 297 | (48.4%) | 287 | (46.9%) |
Fluoropyrimidine | 233 | (37.9%) | 223 | (36.4%) |
Irinotecan | 160 | (26.1%) | 174 | (28.4%) |
Other | 79 | (12.9%) | 71 | (11.6%) |
Oxaliplatin | 66 | (10.7%) | 53 | (8.7%) |
Othera | 6 | (1.0%) | 5 | (0.8%) |
ainclude patients randomized in placebo control trials for whom exact nature of the treatment is unknown | ||||
A patient can be counted both in chemotherapy and biologies (categories can not be added). |
TABLE 16 |
Summary of the most frequent TEAEs: incidence ≥20% in aflibercept |
arm or (incidence <20% in aflibercept arm and Δ all grades ≥5%) - Safety |
population |
% of | |||||
patients (in | Placebo/Folfiri | Aflibercept/Folfiri | |||
the safety | N = 605 | N = 611 | Δ≥10% | 5 ≤ Δ < 10 | Δ≥2% |
population) | All Gr | Gr 3/4 | All Gr | Gr 3/4 | all Gr | all Gr | Gr 3/4 |
Incidence ≥20% (aflibercept arm) |
Diarrhea | 56.5 | 7.8 | 69.2 | 19.3 | X | X | |
(PT) | |||||||
Asthenic | 50.2 | 10.6 | 60.4 | 16.9 | X | X | |
condition | |||||||
(HLT) | |||||||
Stomatitis & | 34.9 | 5.0 | 54.8 | 13.7 | X | X | |
ulceration | |||||||
(HLT) | |||||||
Nausea (PT) | 54.0 | 3.0 | 53.4 | 1.8 | |||
Infections | 32.7 | 6.9 | 46.2 | 12.3 | X | X | |
(SOC) | |||||||
Hypertension | 10.7 | 1.5 | 41.4 | 19.3 | X | X | |
(grouping) | |||||||
GI and | 29.1 | 3.3 | 34.0 | 5.4 | |||
abdominal | |||||||
pains (HLT) | |||||||
Vomiting | 33.4 | 3.5 | 32.9 | 2.8 | |||
(PT) | |||||||
Decrease | 23.8 | 1.8 | 31.9 | 3.4 | X | ||
appetite | |||||||
(PT) | |||||||
Weight | 14.4 | 0.8 | 31.9 | 2.6 | X | ||
decrease | |||||||
(PT) | |||||||
Epistaxis | 7.4 | 0 | 27.7 | 0.2 | X | ||
(PT) | |||||||
Alopecia | 30.1 | NA | 26.8 | NA | |||
(PT) | |||||||
Dysphonia | 3.3 | 0 | 25.4 | 0.5 | X | ||
(PT) | |||||||
Musculoskeletal & | 21.2 | 2.3 | 23.1 | 1.3 | |||
connective | |||||||
pain & | |||||||
discomfort | |||||||
(HLT) | |||||||
Constipation | 24.6 | 1.0 | 22.4 | 0.8 | |||
(PT) | |||||||
Headache | 8.8 | 0.3 | 22.3 | 1.6 | X | ||
(PT) |
Incidence <20% (aflibercept arm) and Δ all grades ≥5% |
Palmar | 4.3 | 0.5 | 11.0 | 2.8 | X | ||
plantar | |||||||
erythrodysa | |||||||
esthesia | |||||||
(PT) | |||||||
Dehydration | 3.0 | 1.3 | 9.0 | 4.3 | X | ||
(PT) | |||||||
Skin | 2.8 | 0 | 8.2 | 0 | X | ||
hyperpigmentation | |||||||
(PT) | |||||||
Medra classification: SOC (system organ class), HLT (high level term), PT (Preferred term). | |||||||
Grouping: grouping of selected PTs | |||||||
Δ: difference in incidence in aflibercept arm compared to placebo |
TABLE 17 |
Overview of safety, number (%) of patients - Safety population |
Placebo/Folfiri | Aflibercept/Folfiri | ||
(N = 605) | (N = 611) | ||
Patients with any TEAE | 592 (97.9%) | 606 (99.2%) |
Patients with any grade 3-4 TEAE | 378 (62.5%) | 510 (83.5%) |
Patients with any serious TEAE | 198 (32.7%) | 294 (48.1%) |
Patients with any TEAE | 29 (4.8%) | 37 (6.1%) |
leading to death | ||
Patients with any related | 3 (0.5%) | 6 (1.0%) |
TEAE leading to death | ||
Patients with any TEAE | 73 (12.1%) | 164 (26.8%) |
leading to permanent | ||
treatment discontinuation | ||
Patients with any TEAE | 17 (2.8%) | 119 (19.5%) |
leading to premature | ||
treatment discontinuation | ||
Note: | ||
Adverse Events are reported using MedDRA version MEDDRA13.1 and graded using NCI CTC Version 3.0. |
Claims (20)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP1305490 | 2011-04-26 | ||
EP11305490.2 | 2011-04-26 | ||
EP11305490 | 2011-04-26 | ||
EP11306154 | 2011-09-15 | ||
EP1306154 | 2011-09-15 | ||
EP11306154.3 | 2011-09-15 | ||
PCT/EP2012/057542 WO2012146610A1 (en) | 2011-04-26 | 2012-04-25 | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) |
Publications (2)
Publication Number | Publication Date |
---|---|
US20140051642A1 US20140051642A1 (en) | 2014-02-20 |
US11033606B2 true US11033606B2 (en) | 2021-06-15 |
Family
ID=46001286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/113,757 Active 2034-07-04 US11033606B2 (en) | 2011-04-26 | 2012-04-25 | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) |
Country Status (38)
Country | Link |
---|---|
US (1) | US11033606B2 (en) |
EP (2) | EP2701724B1 (en) |
JP (1) | JP6114257B2 (en) |
KR (2) | KR102002653B1 (en) |
CN (1) | CN103608029A (en) |
AR (1) | AR086051A1 (en) |
AU (1) | AU2012247530B2 (en) |
BR (1) | BR112013027356A2 (en) |
CA (1) | CA2833592A1 (en) |
CL (1) | CL2013003082A1 (en) |
CO (1) | CO6811861A2 (en) |
CR (1) | CR20130547A (en) |
CY (1) | CY1120382T1 (en) |
DK (1) | DK2701724T3 (en) |
DO (1) | DOP2013000248A (en) |
EA (1) | EA025182B1 (en) |
EC (1) | ECSP13013044A (en) |
ES (1) | ES2637074T3 (en) |
GT (1) | GT201300260A (en) |
HR (1) | HRP20171216T1 (en) |
HU (1) | HUE034288T2 (en) |
IL (2) | IL228947B (en) |
JO (1) | JO3283B1 (en) |
LT (1) | LT2701724T (en) |
MA (1) | MA35130B1 (en) |
MX (1) | MX341348B (en) |
NI (1) | NI201300112A (en) |
PE (2) | PE20140616A1 (en) |
PL (1) | PL2701724T3 (en) |
PT (1) | PT2701724T (en) |
RS (1) | RS56177B1 (en) |
SG (2) | SG194613A1 (en) |
SI (1) | SI2701724T1 (en) |
TW (1) | TWI599369B (en) |
UA (1) | UA114708C2 (en) |
UY (1) | UY34036A (en) |
WO (1) | WO2012146610A1 (en) |
ZA (1) | ZA201308821B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3283B1 (en) | 2011-04-26 | 2018-09-16 | Sanofi Sa | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) |
AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
CA2888281A1 (en) * | 2012-08-02 | 2014-02-06 | Sanofi | Article of manufacture comprising aflibercept or ziv-aflibercept |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
LT3170005T (en) * | 2014-07-18 | 2019-07-10 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
KR102471057B1 (en) | 2014-09-16 | 2022-11-28 | 리제너론 파아마슈티컬스, 인크. | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
JP2018528185A (en) | 2015-08-21 | 2018-09-27 | イプセン バイオファーム リミティド | Method for treating metastatic pancreatic cancer using combination therapy comprising liposomal irinotecan and oxaliplatin |
KR101936049B1 (en) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | Method for manufacturing fusion proteins with IgG Fc domain |
EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
CN108496084B (en) * | 2016-01-25 | 2021-11-05 | 赛诺菲 | Method for predicting the outcome of a treatment with aflibercept in a patient suspected of having a cancer by measuring the level of a plasma biomarker |
AU2017354903B2 (en) | 2016-11-02 | 2023-04-13 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
CN112203679A (en) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | IL-6 antibodies and fusion constructs and conjugates thereof |
MA52570A (en) | 2018-05-10 | 2021-03-17 | Regeneron Pharma | FORMULATIONS CONTAINING HIGH CONCENTRATION VEGF RECEPTOR FUSION PROTEINS |
JP2021526161A (en) * | 2018-05-30 | 2021-09-30 | マショーヴァー, デイビィッドMACHOVER, David | Methods and pharmaceutical compositions for the treatment of cancer |
WO2021050094A1 (en) * | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Citations (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2462908A1 (en) | 1979-08-16 | 1981-02-20 | Ciba Geigy Ag | SECURE APPARATUS FOR DELAYED AND CONTROLLED DELIVERY OF ACTIVE SUBSTANCE |
JPS6019790B2 (en) | 1977-11-18 | 1985-05-17 | 株式会社日立製作所 | Photocurable adhesive composition and method for bonding adherends using it |
US4604463A (en) | 1983-07-14 | 1986-08-05 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
WO1993000807A1 (en) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
WO1994021679A1 (en) | 1993-03-25 | 1994-09-29 | Merck & Co., Inc. | Inhibitor of vascular endothelial cell growth factor |
US5399670A (en) | 1992-04-30 | 1995-03-21 | Alpha Therapeutic Corporation | Solubilization and stabilization of factor VIII complex |
US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
WO1996031513A1 (en) | 1995-04-07 | 1996-10-10 | Pharmacia & Upjohn Company | Novel intermediates and process for the manufacture of camptothecin derivatives (cpt-11) and related compounds |
WO1997044453A1 (en) | 1996-05-07 | 1997-11-27 | Genentech, Inc. | Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
WO1998013071A1 (en) | 1996-09-24 | 1998-04-02 | Merck & Co., Inc. | Gene therapy for inhibition of angiogenesis |
US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
DE19724793A1 (en) | 1997-06-06 | 1998-12-10 | Schering Ag | New peptides inhibit vascular endothelial cell growth factor |
US5851999A (en) | 1992-11-13 | 1998-12-22 | Max-Planck-Gesellschaft zur Forderung der Wissenschaften ev. | FLK-1 is a receptor for vascular endothelial growth factor |
WO1999003996A1 (en) | 1997-07-17 | 1999-01-28 | Regeneron Pharmaceuticals, Inc. | Modified dorsal tissue affecting factor and compositions |
JPH1180024A (en) | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | Corneal vascular rebirth inhibitor |
US6011003A (en) | 1994-05-26 | 2000-01-04 | Metris Therapeutics Limited | FLT-4(FMS-like tyrosine kinase), FLT-15, variants thereof used as growth factor inhibitors |
DE19841985A1 (en) | 1998-09-03 | 2000-03-09 | Schering Ag | New heterocyclic alkanesulfonic and alkane carboxylic acid derivatives are VEGF receptor blockers useful in treatment of e.g. psoriasis, rheumatoid arthritis, stroke, tumors and endometriosis |
US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
WO2000034337A1 (en) | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
US6121230A (en) | 1994-05-26 | 2000-09-19 | Metris Therapeutics Limited | Anti-VEGF agents in the treatment of endometriosis |
WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
WO2000075319A1 (en) | 1999-06-08 | 2000-12-14 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
WO2001012416A1 (en) | 1999-08-16 | 2001-02-22 | Tetra Laval Holdings & Finance S.A. | Device for the production of plastic containers by stretch blow forming using an explosive blowing medium |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6270993B1 (en) | 1995-10-07 | 2001-08-07 | Toa Gosei Co., Ltd. | VEGF-binding polypeptide |
WO2001085789A2 (en) | 2000-05-10 | 2001-11-15 | Bayer Corporation | Extracellular domain of ryk protein for regulating angiogenesis |
US20020004478A1 (en) | 1998-06-01 | 2002-01-10 | Stephen Danko | Pharmaceutical formulations for igf/igfbp |
US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
WO2002060489A1 (en) | 2001-01-31 | 2002-08-08 | Regeneron Pharmaceuticals, Inc. | Method of using a variant of vegf receptor to treat psoriasis and to enhance wound healing |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
US20030092019A1 (en) | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
US20030092606A1 (en) | 1997-01-08 | 2003-05-15 | L'italien James | Formulations for amylin agonist peptides |
US20030113316A1 (en) | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
US20030144298A1 (en) | 2000-04-05 | 2003-07-31 | Curwen Jon Owen | Therapeutic combinations of antihypertensive and antiangiogenics agents |
WO2003074527A1 (en) | 2002-03-01 | 2003-09-12 | Pharmacia Italia S.P.A. | Crystalline polymorphic form of irinotecan hydrochloride |
US20030202972A1 (en) | 1995-07-27 | 2003-10-30 | Genentech, Inc. | Protein formulation |
US20040014667A1 (en) | 1999-06-08 | 2004-01-22 | Daly Thomas J. | VEGF traps and therapeutic uses thereof |
US20040023864A1 (en) | 2001-05-09 | 2004-02-05 | Steve Roczniak | Method of regulating angiogenesis using ryk protein |
US6733782B1 (en) | 1999-02-01 | 2004-05-11 | Les Laboratories Servier | Core tablet for controlled release of gliclazide after oral administration |
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US20040197324A1 (en) | 2003-04-04 | 2004-10-07 | Genentech, Inc. | High concentration antibody and protein formulations |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
WO2004106378A2 (en) | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using vegf antagonists |
WO2004110490A2 (en) | 2003-06-06 | 2004-12-23 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for tumor regression |
WO2005000220A2 (en) | 2003-06-03 | 2005-01-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
US20050032699A1 (en) | 2003-07-25 | 2005-02-10 | Jocelyn Holash | Composition of a VEGF antagonist and an anti-proliferative agent |
WO2005017734A1 (en) | 2003-08-14 | 2005-02-24 | Fujitsu Limited | Computer device and cluster server device |
WO2005020972A2 (en) | 2003-08-27 | 2005-03-10 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of ocular neovascular disorders |
US6875432B2 (en) | 2000-10-12 | 2005-04-05 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
WO2005044540A1 (en) | 2003-11-06 | 2005-05-19 | Nestle Waters Management & Technology | Container made of polyester resin, its manufacturing process and device for its implementation |
US20050112061A1 (en) | 2003-08-06 | 2005-05-26 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
US20050175610A1 (en) | 1999-06-08 | 2005-08-11 | Wiegand Stanley J. | Modified chimeric polypeptides with improved pharmacokinetic properties and methods of making and using thereof |
US20050196340A1 (en) | 2003-08-06 | 2005-09-08 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
US20050196396A1 (en) | 2003-11-10 | 2005-09-08 | Greenville Hospital System | VEGF receptor antagonists |
US20050260203A1 (en) | 1999-06-08 | 2005-11-24 | Wiegand Stanley J | Use of VEGF inhibitors for treatment of eye disorders |
US20050276808A1 (en) | 2004-06-10 | 2005-12-15 | Cedarbaum Jesse M | Method of administering and using VEGF inhibitors for the treatment of human cancer |
US20050281822A1 (en) | 2004-06-18 | 2005-12-22 | Cedarbaum Jesse M | Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion |
US6987294B2 (en) | 2002-03-22 | 2006-01-17 | Sanyo Electric Co., Ltd. | Charge-coupled device and method of fabricating the same |
US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
US20060058234A1 (en) | 1999-06-08 | 2006-03-16 | Daly Thomas J | VEGF traps and therapeutic uses thereof |
WO2006047325A1 (en) | 2004-10-21 | 2006-05-04 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
US7052691B2 (en) | 2003-03-28 | 2006-05-30 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking VEGF-mediated activity |
WO2006059012A1 (en) | 2004-12-03 | 2006-06-08 | Aventis Pharma S.A. | Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivatives |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US20060148705A1 (en) | 2003-06-30 | 2006-07-06 | Daly Thomas J | VEGF-binding fusion proteins and therapeutic uses thereof |
US20060172944A1 (en) | 2005-02-02 | 2006-08-03 | Wiegand Stanley J | Method of treating eye injury with local administration of a VEGF inhibitor |
US20060210566A1 (en) | 2005-03-11 | 2006-09-21 | Jocelyn Holash | Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF) |
US20060217311A1 (en) | 2005-03-25 | 2006-09-28 | Daniel Dix | VEGF antagonist formulations |
US20070037748A1 (en) | 2005-08-12 | 2007-02-15 | Regneron Pharmaceuticals, Inc. | Methods of treating diseases with a VEGF antagonist |
US7300654B2 (en) | 2003-05-28 | 2007-11-27 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection in high risk keratoplasty patients |
WO2007149334A2 (en) | 2006-06-16 | 2007-12-27 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
US7354582B2 (en) | 2006-03-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Use of VEGF antagonists for the treatment of malignant gliomas |
US7354581B2 (en) | 2005-02-11 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a VEGF antagonist and anti-hypertensive agent |
US7378095B2 (en) | 2004-07-30 | 2008-05-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
WO2008076379A2 (en) | 2006-12-14 | 2008-06-26 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human delta like ligand 4 |
WO2009024667A2 (en) | 2007-07-05 | 2009-02-26 | Aventis Pharma S.A. | Antitumour combinations containing a vegf inhibiting agent and irinotecan |
US20090105156A1 (en) | 2007-10-04 | 2009-04-23 | Proteolix, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
WO2009073540A2 (en) | 2007-11-30 | 2009-06-11 | Schneider Bryan P | Vegf polymorphisms and anti-angiogenesis therapy |
WO2010003853A1 (en) | 2008-07-07 | 2010-01-14 | Nestec S.A. | Method and apparatus for packaging a liquid food product |
WO2010022201A2 (en) | 2008-08-22 | 2010-02-25 | Osteogenex Inc. | Folinic acid derivatives for promoting bone growth |
US20100093552A1 (en) | 2008-10-09 | 2010-04-15 | Asit Panja | Use and identification of biomarkers for gastrointestinal diseases |
WO2010054110A2 (en) | 2008-11-05 | 2010-05-14 | Genentech, Inc. | Genetic polymorphisms in age-related macular degeneration |
US20100216168A1 (en) | 2007-03-23 | 2010-08-26 | Precision Therapeutics, Inc. | Methods for evaluating angiogenic potential in culture |
WO2010112413A1 (en) | 2009-03-31 | 2010-10-07 | Roche Glycart Ag | Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan |
WO2010124264A2 (en) | 2009-04-24 | 2010-10-28 | University Of Southern California | Genetic variants in angiogenesis pathway associated with clinical outcome |
WO2011014759A2 (en) | 2009-07-31 | 2011-02-03 | Amcor Limited | Hot-fill container |
WO2011041441A1 (en) | 2009-09-30 | 2011-04-07 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
US20110150903A1 (en) | 2008-07-08 | 2011-06-23 | Sanofi-Aventis | Fgf-r4 receptor-specific antagonists |
WO2012146610A1 (en) | 2011-04-26 | 2012-11-01 | Sanofi | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) |
US20130330341A1 (en) | 2011-02-23 | 2013-12-12 | Sanofi | Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments |
US20150216795A1 (en) | 2012-08-02 | 2015-08-06 | Sanofi | Article of manufacture comprising aflibercept or ziv-aflibercept |
WO2016008975A1 (en) | 2014-07-18 | 2016-01-21 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
JP6019790B2 (en) | 2012-06-19 | 2016-11-02 | 富士電機株式会社 | Joining method and joining member |
WO2017129537A1 (en) | 2016-01-25 | 2017-08-03 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100546578C (en) * | 2007-08-10 | 2009-10-07 | 河北医科大学 | A kind of anticancer pharmaceutical composition and the application in the preparation cancer therapy drug thereof |
-
2012
- 2012-04-24 JO JOP/2012/0097A patent/JO3283B1/en active
- 2012-04-25 BR BR112013027356A patent/BR112013027356A2/en not_active Application Discontinuation
- 2012-04-25 PE PE2013002411A patent/PE20140616A1/en not_active Application Discontinuation
- 2012-04-25 WO PCT/EP2012/057542 patent/WO2012146610A1/en active Application Filing
- 2012-04-25 SG SG2013079058A patent/SG194613A1/en unknown
- 2012-04-25 EP EP12717129.6A patent/EP2701724B1/en active Active
- 2012-04-25 LT LTEP12717129.6T patent/LT2701724T/en unknown
- 2012-04-25 AU AU2012247530A patent/AU2012247530B2/en active Active
- 2012-04-25 MX MX2013012387A patent/MX341348B/en active IP Right Grant
- 2012-04-25 US US14/113,757 patent/US11033606B2/en active Active
- 2012-04-25 KR KR1020137030891A patent/KR102002653B1/en active IP Right Grant
- 2012-04-25 EP EP17157891.7A patent/EP3210617A1/en not_active Withdrawn
- 2012-04-25 PL PL12717129T patent/PL2701724T3/en unknown
- 2012-04-25 HU HUE12717129A patent/HUE034288T2/en unknown
- 2012-04-25 CA CA2833592A patent/CA2833592A1/en active Pending
- 2012-04-25 AR ARP120101420A patent/AR086051A1/en unknown
- 2012-04-25 EA EA201391577A patent/EA025182B1/en not_active IP Right Cessation
- 2012-04-25 PT PT127171296T patent/PT2701724T/en unknown
- 2012-04-25 UA UAA201313713A patent/UA114708C2/en unknown
- 2012-04-25 RS RS20170801A patent/RS56177B1/en unknown
- 2012-04-25 SI SI201231040T patent/SI2701724T1/en unknown
- 2012-04-25 SG SG10201610829UA patent/SG10201610829UA/en unknown
- 2012-04-25 DK DK12717129.6T patent/DK2701724T3/en active
- 2012-04-25 CN CN201280031198.9A patent/CN103608029A/en active Pending
- 2012-04-25 PE PE2017001505A patent/PE20171516A1/en unknown
- 2012-04-25 JP JP2014506843A patent/JP6114257B2/en active Active
- 2012-04-25 KR KR1020197020546A patent/KR20190088568A/en not_active Application Discontinuation
- 2012-04-25 ES ES12717129.6T patent/ES2637074T3/en active Active
- 2012-04-26 TW TW101115009A patent/TWI599369B/en active
- 2012-04-26 UY UY0001034036A patent/UY34036A/en not_active Application Discontinuation
-
2013
- 2013-10-17 IL IL228947A patent/IL228947B/en active IP Right Grant
- 2013-10-18 NI NI201300112A patent/NI201300112A/en unknown
- 2013-10-22 DO DO2013000248A patent/DOP2013000248A/en unknown
- 2013-10-23 GT GT201300260A patent/GT201300260A/en unknown
- 2013-10-24 CL CL2013003082A patent/CL2013003082A1/en unknown
- 2013-10-24 CR CR20130547A patent/CR20130547A/en unknown
- 2013-11-20 MA MA36457A patent/MA35130B1/en unknown
- 2013-11-22 ZA ZA2013/08821A patent/ZA201308821B/en unknown
- 2013-11-25 EC ECSP13013044 patent/ECSP13013044A/en unknown
- 2013-11-26 CO CO13277422A patent/CO6811861A2/en unknown
-
2017
- 2017-08-08 HR HRP20171216TT patent/HRP20171216T1/en unknown
- 2017-08-22 CY CY20171100890T patent/CY1120382T1/en unknown
-
2018
- 2018-01-28 IL IL257179A patent/IL257179A/en unknown
Patent Citations (188)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019790B2 (en) | 1977-11-18 | 1985-05-17 | 株式会社日立製作所 | Photocurable adhesive composition and method for bonding adherends using it |
US4353887A (en) | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
FR2462908A1 (en) | 1979-08-16 | 1981-02-20 | Ciba Geigy Ag | SECURE APPARATUS FOR DELAYED AND CONTROLLED DELIVERY OF ACTIVE SUBSTANCE |
US4604463A (en) | 1983-07-14 | 1986-08-05 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
WO1993000807A1 (en) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
US5399670A (en) | 1992-04-30 | 1995-03-21 | Alpha Therapeutic Corporation | Solubilization and stabilization of factor VIII complex |
US5851999A (en) | 1992-11-13 | 1998-12-22 | Max-Planck-Gesellschaft zur Forderung der Wissenschaften ev. | FLK-1 is a receptor for vascular endothelial growth factor |
WO1994021679A1 (en) | 1993-03-25 | 1994-09-29 | Merck & Co., Inc. | Inhibitor of vascular endothelial cell growth factor |
US5712380A (en) | 1993-03-25 | 1998-01-27 | Merck & Co., Inc. | DNA encoding a soluble VEGF inhibitor |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US6121230A (en) | 1994-05-26 | 2000-09-19 | Metris Therapeutics Limited | Anti-VEGF agents in the treatment of endometriosis |
US6011003A (en) | 1994-05-26 | 2000-01-04 | Metris Therapeutics Limited | FLT-4(FMS-like tyrosine kinase), FLT-15, variants thereof used as growth factor inhibitors |
WO1996031513A1 (en) | 1995-04-07 | 1996-10-10 | Pharmacia & Upjohn Company | Novel intermediates and process for the manufacture of camptothecin derivatives (cpt-11) and related compounds |
US7060268B2 (en) | 1995-07-27 | 2006-06-13 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US20030202972A1 (en) | 1995-07-27 | 2003-10-30 | Genentech, Inc. | Protein formulation |
US6270993B1 (en) | 1995-10-07 | 2001-08-07 | Toa Gosei Co., Ltd. | VEGF-binding polypeptide |
US20090234103A1 (en) | 1996-05-07 | 2009-09-17 | Genentech, Inc. | Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
US20050281831A1 (en) | 1996-05-07 | 2005-12-22 | Genentech, Inc. | Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
US6897294B2 (en) | 1996-05-07 | 2005-05-24 | Genentech, Inc. | Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
WO1997044453A1 (en) | 1996-05-07 | 1997-11-27 | Genentech, Inc. | Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
WO1998013071A1 (en) | 1996-09-24 | 1998-04-02 | Merck & Co., Inc. | Gene therapy for inhibition of angiogenesis |
US20030092606A1 (en) | 1997-01-08 | 2003-05-15 | L'italien James | Formulations for amylin agonist peptides |
DE19724793A1 (en) | 1997-06-06 | 1998-12-10 | Schering Ag | New peptides inhibit vascular endothelial cell growth factor |
WO1999003996A1 (en) | 1997-07-17 | 1999-01-28 | Regeneron Pharmaceuticals, Inc. | Modified dorsal tissue affecting factor and compositions |
WO1999013909A1 (en) | 1997-09-12 | 1999-03-25 | Toagosei Co., Ltd. | Corneal neovascularization inhibitors |
JPH1180024A (en) | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | Corneal vascular rebirth inhibitor |
US20020004478A1 (en) | 1998-06-01 | 2002-01-10 | Stephen Danko | Pharmaceutical formulations for igf/igfbp |
DE19841985A1 (en) | 1998-09-03 | 2000-03-09 | Schering Ag | New heterocyclic alkanesulfonic and alkane carboxylic acid derivatives are VEGF receptor blockers useful in treatment of e.g. psoriasis, rheumatoid arthritis, stroke, tumors and endometriosis |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
WO2000034337A1 (en) | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
US6733782B1 (en) | 1999-02-01 | 2004-05-11 | Les Laboratories Servier | Core tablet for controlled release of gliclazide after oral administration |
US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
US6524583B1 (en) | 1999-04-28 | 2003-02-25 | Board Of Regents, The University Of Texas System | Antibody methods for selectively inhibiting VEGF |
WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US20040014667A1 (en) | 1999-06-08 | 2004-01-22 | Daly Thomas J. | VEGF traps and therapeutic uses thereof |
US7521049B2 (en) | 1999-06-08 | 2009-04-21 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
WO2000075319A1 (en) | 1999-06-08 | 2000-12-14 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
US7303747B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
US7374758B2 (en) | 1999-06-08 | 2008-05-20 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties and methods of using thereof |
US20030017977A1 (en) | 1999-06-08 | 2003-01-23 | Yuping Xia | Methods of treating inflammatory skin diseases |
JP2003501089A (en) | 1999-06-08 | 2003-01-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7374757B2 (en) | 1999-06-08 | 2008-05-20 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
US20090081217A1 (en) | 1999-06-08 | 2009-03-26 | Regeneron Pharmaceuticals, Inc. | Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US20040266686A1 (en) | 1999-06-08 | 2004-12-30 | Yuping Xia | Methods of treating inflammatory skin diseases |
US7524499B2 (en) | 1999-06-08 | 2009-04-28 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US20160130320A1 (en) | 1999-06-08 | 2016-05-12 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US9139644B2 (en) | 1999-06-08 | 2015-09-22 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US8647842B2 (en) | 1999-06-08 | 2014-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for producing a fusion protein capable of binding VEGF |
US20130084635A1 (en) | 1999-06-08 | 2013-04-04 | Regeneron Pharmaceuticals, Inc. | Cell Culture Compositions Capable of Producing a VEGF-Binding Fusion Polypeptide |
US8343737B2 (en) | 1999-06-08 | 2013-01-01 | Regeneron Pharmaceuticals, Inc. | Cell culture compositions capable of producing a VEGF-binding fusion polypeptide |
US20060058234A1 (en) | 1999-06-08 | 2006-03-16 | Daly Thomas J | VEGF traps and therapeutic uses thereof |
US8084234B2 (en) | 1999-06-08 | 2011-12-27 | Regeneron Pharmaceuticals, Inc. | Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGF |
US20060030529A1 (en) | 1999-06-08 | 2006-02-09 | Wiegand Stanley J | Use of VEGF inhibitors for treatment of eye disorders |
US8029791B2 (en) | 1999-06-08 | 2011-10-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7964377B2 (en) | 1999-06-08 | 2011-06-21 | Regeneron Pharmaceuticals, Inc. | Nucleic acid molecule encoding a fusion polypeptide capable of binding VEGF |
US20050175610A1 (en) | 1999-06-08 | 2005-08-11 | Wiegand Stanley J. | Modified chimeric polypeptides with improved pharmacokinetic properties and methods of making and using thereof |
US20110028698A1 (en) | 1999-06-08 | 2011-02-03 | Regenron Pharmaceuticals, Inc. | Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties |
US20100221782A1 (en) | 1999-06-08 | 2010-09-02 | Regeneron Pharmaceuticals, Inc. | Modified Chimeric Polypeptides With Improved Pharmacokinetic Properties |
US20050260203A1 (en) | 1999-06-08 | 2005-11-24 | Wiegand Stanley J | Use of VEGF inhibitors for treatment of eye disorders |
US7704500B2 (en) | 1999-06-08 | 2010-04-27 | Regeneron Pharmaceuticals, Inc. | Methods of inhibiting ascites formation with modified chimeric VEGF polypeptides |
US20090155899A1 (en) | 1999-06-08 | 2009-06-18 | Regeneron Pharmaceuticals, Inc. | Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties |
US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
WO2001012416A1 (en) | 1999-08-16 | 2001-02-22 | Tetra Laval Holdings & Finance S.A. | Device for the production of plastic containers by stretch blow forming using an explosive blowing medium |
US20030144298A1 (en) | 2000-04-05 | 2003-07-31 | Curwen Jon Owen | Therapeutic combinations of antihypertensive and antiangiogenics agents |
US6500633B1 (en) | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
ECSP014068A (en) | 2000-05-10 | 2002-02-25 | Bayer Corp | PROCEDURE TO REGULATE ANGIOGENESIS USING RYK PROTEIN |
WO2001085789A2 (en) | 2000-05-10 | 2001-11-15 | Bayer Corporation | Extracellular domain of ryk protein for regulating angiogenesis |
US6875432B2 (en) | 2000-10-12 | 2005-04-05 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US20030092019A1 (en) | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
WO2002060489A1 (en) | 2001-01-31 | 2002-08-08 | Regeneron Pharmaceuticals, Inc. | Method of using a variant of vegf receptor to treat psoriasis and to enhance wound healing |
US20040023864A1 (en) | 2001-05-09 | 2004-02-05 | Steve Roczniak | Method of regulating angiogenesis using ryk protein |
US20030113316A1 (en) | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
WO2003074527A1 (en) | 2002-03-01 | 2003-09-12 | Pharmacia Italia S.P.A. | Crystalline polymorphic form of irinotecan hydrochloride |
US6987294B2 (en) | 2002-03-22 | 2006-01-17 | Sanyo Electric Co., Ltd. | Charge-coupled device and method of fabricating the same |
US7052691B2 (en) | 2003-03-28 | 2006-05-30 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking VEGF-mediated activity |
US20040197324A1 (en) | 2003-04-04 | 2004-10-07 | Genentech, Inc. | High concentration antibody and protein formulations |
WO2004106378A2 (en) | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using vegf antagonists |
US7300654B2 (en) | 2003-05-28 | 2007-11-27 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection in high risk keratoplasty patients |
US7300653B2 (en) | 2003-05-28 | 2007-11-27 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection |
WO2005000220A2 (en) | 2003-06-03 | 2005-01-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
US20040265309A1 (en) | 2003-06-06 | 2004-12-30 | Jessica Kandel | Method of tumor regression with VEGF inhibitors |
WO2004110490A2 (en) | 2003-06-06 | 2004-12-23 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for tumor regression |
US7354578B2 (en) | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
US7279159B2 (en) | 2003-06-30 | 2007-10-09 | Regeneron Pharmaceuticals, Inc. | VEGF inhibitor polypeptides |
US7972598B2 (en) | 2003-06-30 | 2011-07-05 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and therapeutic uses thereof |
WO2005000895A2 (en) | 2003-06-30 | 2005-01-06 | Regeneron Pharmaceuticals, Inc. | Vegf traps and therapeutic uses thereof |
US20100087632A1 (en) | 2003-06-30 | 2010-04-08 | Regeneron Pharmaceuticals, Inc. | VEGF-Binding Fusion Proteins and Therapeutic Uses Thereof |
US7635474B2 (en) | 2003-06-30 | 2009-12-22 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins |
US20050043236A1 (en) | 2003-06-30 | 2005-02-24 | Daly Thomas J. | VEGF traps and therapeutic uses thereof |
US20060148705A1 (en) | 2003-06-30 | 2006-07-06 | Daly Thomas J | VEGF-binding fusion proteins and therapeutic uses thereof |
US7399612B2 (en) | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
US20090062200A1 (en) | 2003-06-30 | 2009-03-05 | Regeneron Pharmaceuticals, Inc. | VEGF-Binding Fusion Proteins and Therapeutic Uses Thereof |
US7354579B2 (en) | 2003-07-25 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of treating cancer with a VEGF antagonist and an anti-proliferative agent |
JP2007500131A (en) | 2003-07-25 | 2007-01-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Compositions of VEGF antagonists and antiproliferative agents and their use for the treatment of cancer |
US20050032699A1 (en) | 2003-07-25 | 2005-02-10 | Jocelyn Holash | Composition of a VEGF antagonist and an anti-proliferative agent |
US20050112061A1 (en) | 2003-08-06 | 2005-05-26 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
US20050196340A1 (en) | 2003-08-06 | 2005-09-08 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
WO2005017734A1 (en) | 2003-08-14 | 2005-02-24 | Fujitsu Limited | Computer device and cluster server device |
WO2005020972A2 (en) | 2003-08-27 | 2005-03-10 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of ocular neovascular disorders |
WO2005044540A1 (en) | 2003-11-06 | 2005-05-19 | Nestle Waters Management & Technology | Container made of polyester resin, its manufacturing process and device for its implementation |
US20050196396A1 (en) | 2003-11-10 | 2005-09-08 | Greenville Hospital System | VEGF receptor antagonists |
WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
US7479273B2 (en) | 2004-06-10 | 2009-01-20 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of renal cell cancer |
US20050276808A1 (en) | 2004-06-10 | 2005-12-15 | Cedarbaum Jesse M | Method of administering and using VEGF inhibitors for the treatment of human cancer |
US7479272B2 (en) | 2004-06-10 | 2009-01-20 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of breast cancer |
US7479275B2 (en) | 2004-06-10 | 2009-01-20 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of colorectal cancer |
US7479274B2 (en) | 2004-06-10 | 2009-01-20 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of pancreatic carcinoma |
US7482002B2 (en) | 2004-06-10 | 2009-01-27 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of prostate cancer |
US7482001B2 (en) | 2004-06-10 | 2009-01-27 | Cedarbaum Jesse M | Method of administering and using VEGF inhibitors for the treatment of non small cell lung cancer |
US7354580B2 (en) | 2004-06-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of human cancer |
CN1968709A (en) | 2004-06-18 | 2007-05-23 | 瑞泽恩制药公司 | VEGF inhibitors for the treatment of malignant pleural effusion |
US20050281822A1 (en) | 2004-06-18 | 2005-12-22 | Cedarbaum Jesse M | Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion |
WO2006009809A2 (en) | 2004-06-18 | 2006-01-26 | Regeneron Pharmaceuticals, Inc. | Vegf inhibitors for the treatment of malignant pleural effusion |
US7378095B2 (en) | 2004-07-30 | 2008-05-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
WO2006047325A1 (en) | 2004-10-21 | 2006-05-04 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
US20130184205A1 (en) | 2004-12-03 | 2013-07-18 | Aventis Pharma S.A. | Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof |
WO2006059012A1 (en) | 2004-12-03 | 2006-06-08 | Aventis Pharma S.A. | Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivatives |
US8388963B2 (en) | 2004-12-03 | 2013-03-05 | Aventis Pharma Sa | Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof |
US20060178305A1 (en) | 2004-12-03 | 2006-08-10 | Aventis Pharma S.A. | Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof |
JP2008521866A (en) | 2004-12-03 | 2008-06-26 | アバンテイス・フアルマ・エス・アー | Anti-tumor combination containing a VEGF inhibitor and 5FU or one of its derivatives |
US20060172944A1 (en) | 2005-02-02 | 2006-08-03 | Wiegand Stanley J | Method of treating eye injury with local administration of a VEGF inhibitor |
US7531173B2 (en) | 2005-02-02 | 2009-05-12 | Regeneron Pharmaceuticals, Inc. | Ophthalmic composition of a VEGF antagonist |
US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
US7354581B2 (en) | 2005-02-11 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a VEGF antagonist and anti-hypertensive agent |
US7449182B2 (en) | 2005-02-11 | 2008-11-11 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a VEGF antagonist and anti-hypertensive agent |
US7351411B2 (en) | 2005-03-11 | 2008-04-01 | Regeneron Pharmaceuticals, Inc. | Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF) |
US20060210566A1 (en) | 2005-03-11 | 2006-09-21 | Jocelyn Holash | Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF) |
US8921316B2 (en) | 2005-03-25 | 2014-12-30 | Regeneron Pharmaceuticals, Inc. | Stable liquid VEGF antagonist formulations |
US20160244504A1 (en) | 2005-03-25 | 2016-08-25 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
US8710004B2 (en) | 2005-03-25 | 2014-04-29 | Regeneron Pharmaceuticals, Inc. | Stable liquid VEGF antagonist formulations |
US8404638B2 (en) | 2005-03-25 | 2013-03-26 | Regeneron Pharmaceuticals, Inc. | Dimer VEGF antagonist formulations |
US8110546B2 (en) | 2005-03-25 | 2012-02-07 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations |
US20060217311A1 (en) | 2005-03-25 | 2006-09-28 | Daniel Dix | VEGF antagonist formulations |
WO2006104852A2 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations |
US9416167B2 (en) | 2005-03-25 | 2016-08-16 | Regeneron Pharmaceuticals, Inc. | Stable liquid formulations of dimer VEGF antagonists |
US9511140B2 (en) | 2005-03-25 | 2016-12-06 | Regeneron Pharmaceuticals, Inc. | Stable VEGF antagonist formulations |
US20070037748A1 (en) | 2005-08-12 | 2007-02-15 | Regneron Pharmaceuticals, Inc. | Methods of treating diseases with a VEGF antagonist |
US7531172B2 (en) | 2005-08-12 | 2009-05-12 | Regeneron Pharmaceuticals, Inc. | Methods of treating diseases with a VEGF antagonist |
US7354582B2 (en) | 2006-03-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Use of VEGF antagonists for the treatment of malignant gliomas |
US9340594B2 (en) | 2006-06-16 | 2016-05-17 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations for intravitreal administration |
US20160244505A1 (en) | 2006-06-16 | 2016-08-25 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
WO2007149334A2 (en) | 2006-06-16 | 2007-12-27 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
US8481046B2 (en) | 2006-06-16 | 2013-07-09 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations for intravitreal administration |
US20160213608A1 (en) | 2006-06-16 | 2016-07-28 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
US7807164B2 (en) | 2006-06-16 | 2010-10-05 | Regeneron Pharmaceuticals, Inc. | Lyophilized VEGF antagonist formulations for intravitreal administration |
US8092803B2 (en) | 2006-06-16 | 2012-01-10 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations for intravitreal administration |
US8802107B2 (en) | 2006-06-16 | 2014-08-12 | Regeneron Pharmaceuticals, Inc | VEGF antagonist formulations for intravitreal administration |
US7608261B2 (en) | 2006-06-16 | 2009-10-27 | Regeneron Pharmacuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
WO2008076379A2 (en) | 2006-12-14 | 2008-06-26 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human delta like ligand 4 |
US7919593B2 (en) | 2006-12-14 | 2011-04-05 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human delta like ligand 4 |
US20100216168A1 (en) | 2007-03-23 | 2010-08-26 | Precision Therapeutics, Inc. | Methods for evaluating angiogenic potential in culture |
WO2009024667A2 (en) | 2007-07-05 | 2009-02-26 | Aventis Pharma S.A. | Antitumour combinations containing a vegf inhibiting agent and irinotecan |
US20140127202A1 (en) | 2007-07-05 | 2014-05-08 | Aventis Pharma S.A. | Antitumour combinations containing a vegf inhibiting agent and irinotecan |
JP2010532335A (en) | 2007-07-05 | 2010-10-07 | アバンテイス・フアルマ・エス・アー | Anti-tumor combination comprising a VEGF inhibitor and irinotecan |
US20190275147A1 (en) | 2007-07-05 | 2019-09-12 | Aventis Pharma S.A. | Antitumour combinations containing a vegf inhibiting agent and irinotecan |
US20100160233A1 (en) | 2007-07-05 | 2010-06-24 | Aventis Pharma S.A. | Antitumour combinations containing a vegf inhibiting agent and irinotecan |
US20090105156A1 (en) | 2007-10-04 | 2009-04-23 | Proteolix, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
WO2009073540A2 (en) | 2007-11-30 | 2009-06-11 | Schneider Bryan P | Vegf polymorphisms and anti-angiogenesis therapy |
US20110176993A1 (en) | 2007-11-30 | 2011-07-21 | Schneider Bryan P | Vegf polymorphisms and anti-angiogenesis therapy |
WO2010003853A1 (en) | 2008-07-07 | 2010-01-14 | Nestec S.A. | Method and apparatus for packaging a liquid food product |
US20110150903A1 (en) | 2008-07-08 | 2011-06-23 | Sanofi-Aventis | Fgf-r4 receptor-specific antagonists |
WO2010022201A2 (en) | 2008-08-22 | 2010-02-25 | Osteogenex Inc. | Folinic acid derivatives for promoting bone growth |
US20100093552A1 (en) | 2008-10-09 | 2010-04-15 | Asit Panja | Use and identification of biomarkers for gastrointestinal diseases |
WO2010054110A2 (en) | 2008-11-05 | 2010-05-14 | Genentech, Inc. | Genetic polymorphisms in age-related macular degeneration |
WO2010112413A1 (en) | 2009-03-31 | 2010-10-07 | Roche Glycart Ag | Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan |
WO2010124264A2 (en) | 2009-04-24 | 2010-10-28 | University Of Southern California | Genetic variants in angiogenesis pathway associated with clinical outcome |
WO2011014759A2 (en) | 2009-07-31 | 2011-02-03 | Amcor Limited | Hot-fill container |
WO2011041441A1 (en) | 2009-09-30 | 2011-04-07 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
US20130330341A1 (en) | 2011-02-23 | 2013-12-12 | Sanofi | Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments |
WO2012146610A1 (en) | 2011-04-26 | 2012-11-01 | Sanofi | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) |
JP6019790B2 (en) | 2012-06-19 | 2016-11-02 | 富士電機株式会社 | Joining method and joining member |
US20180078496A1 (en) | 2012-08-02 | 2018-03-22 | Sanofi | Article of manufacture comprising aflibercept or ziv-aflibercept |
US20150216795A1 (en) | 2012-08-02 | 2015-08-06 | Sanofi | Article of manufacture comprising aflibercept or ziv-aflibercept |
WO2016008975A1 (en) | 2014-07-18 | 2016-01-21 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
US10501523B2 (en) * | 2014-07-18 | 2019-12-10 | Sanofi | IL-8 level based method of predicting the outcome of colon cancer treatment |
WO2017129537A1 (en) | 2016-01-25 | 2017-08-03 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker |
Non-Patent Citations (260)
Title |
---|
Abajo A., "Identification of Predictive Circulating Biomarkers of Bevacizumab-Containing Regimen Efficacy in Pre-Treated Metastatic Colorectal Cancer Patients," British Journal of Cancer, 2012, vol. 107 (2), pp. 287-290. |
Abajo A., et al., "Dose-Finding Study and Pharmacogenomic Analysis of Fixed-Rate Infusion of Gemcitabine, Irinotecan and Bevacizumab in Pretreated Metastatic Colorectal Cancer Patients," British Journal of Cancer, 2010, vol. 103 (10), pp. 1529-1535. |
Aflibercept, The Merck Index, 15th Edition (2013). |
Allegra C.J. et al., "Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen," J. Clin. Onool. 30, 2012, Suppl.; Abstract 3505. |
Allegra C.J. et al., "Meta-analysis of anti-VEGF class adverse events from three double-blind (Db) placebo (Pbo)-controlled phase III trials with IV aflibercept (Afl)," Journal of Clinical Oncology, 2012 Gastrointestinal Cancers Symposium, vol. 30, No. 4 Suppl. (Feb. 1 Supplement), Abstract 561, 2012. |
Altman E.M., et al., "Diagnosis: Psoriasis or Not? What are the clues?," Seminars in Cutaneous Medicine and Surgery , 1999, vol. 18 (1), pp. 25-35. |
Andre et al., Eur. J. Cancer 35(9), 1243-47 (1999). * |
Anonymous, "Capecitabine/Bevacizumab compared to capecitabine alone in pretreated metastatic breast cancer: results of a phase III study," Clin. Breast Cancer 375-377 (2003). |
Anonymous, "NCT 00045266 VEGF Trap in Treating patients with Solid Tumors or Non-Hodgkin's Lymphoma," pp. 1-4, Retrieved from the Internet: https://clinicaltrials.gov/show/NCT00045266 on Feb. 3, 2017. |
Anonymous, "Starting Therapy with Zaltrap. A Guide for Patients and Caregivers" Aug. 2012 [retrieved-on Sep. 24, 2013], pp. 1-16. Retrieved from the Internet. |
Anonymous: "A Study of Intravenous Aflibercept with Docetaxel in Chinese Patients with Solid Tumors NCT01148615," ClinicalTrials.gov, retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NCT01148615?term=nct01148615&rank=1 [retrieved on Jan. 13, 2015], 2012. |
Anonymous: "View of NCT00561470 on Jul. 26, 2012, Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen," Sanofi-Regeneron 2012 [retrieved on Sep. 25, 2013], pp. 1-5. Retrieved from the Internet: URL:http://clinicaltrials.govjarchive/NCTO0561470/2012_07_26 (retrieved on Sep. 25, 2013). |
Antonelli A., et al., "Anti-CD38 Autoimmunity in Patients with Chronic Autoimmune Thyroiditis or Graves' Disease," Clinical & Experimental Immunology, 2001, vol. 126 (3), pp. 426-431. |
Antonelli A., et al., "Autoimmunity to CD38 and GAD in Type I and Type II Diabetes: CD38 and HLA Genotypes and Clinical Phenotypes," Diabetologia, 2002, vol. 45 (9), pp. 1298-1306. |
Antonelli A., et al., "CD38 Autoimmunity: Recent Advances and Relevance to Human Diabetes," Endocrinological Investigation, 2004, vol. 27 (7), pp. 695-707. |
Antonelli A., et al., "Human Anti-CD38 Autoantibodies Raise Intracellular Calcium and Stimulate Insulin Release in Human Pancreatic Islets," Diabetes, 2001, vol. 50 (5), pp. 985-991. |
Ashkenazi A., et al., "Immunoadhesins: an Alternative to Human Monoclonal Antibodies, Methods: a Companion to Methods in Enzymology," Methods: A Companion to Methods in Enzymology, 1995, vol. 8, pp. 104-115. |
Autiero M., et al., "Role of Plgf in the Intra- and Intermolecular Cross Falk Between the Vegf Receptors Flt1 and Flk1," Nature Medicine, 2003, vol. 9 (7), pp. 936-943. |
Baar J. et al., "A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angigenic Biomarkers," Clinical Cancer Research, vol. 15, No. 10, 2009, pp. 3583-3590. |
Barleon B., et al., "Mapping of the Sites for Ligand Binding and Receptor Dirnerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor Flt-1," The Journal of Biological Chemistry, 1997, vol. 272 (16), pp. 10382-10388. |
Bartlett et al. (Mar. 15, 2012) "Can Metastatic Colorectal Cancer Be Cured?", Home of the journal Oncology, Cancer Network, vol. 26, No. 3, pp. 266-275. |
Bender et al. (Sep. 15, 2012) "A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report", Clinical Cancer Research, vol. 18, No. 18, pp. 5081-5089. |
Blann A.D., et al., "Vascular Endothelial Growth Factor and Its Receptor, Flt-1, in the Plasma of Patients with Coronary or Peripheral Atherosclerosis, or Type II Diabetes," Clinical Science, 2002, vol. 102 (2), pp. 187-194. |
Bork P., et al., "Go Hunting in Sequence Databases But Watch Out for the Traps," Trends in Genetics, 1996, vol. 12 (10), pp. 425-457. |
Bork P., et al., "Powers and Pitfalls in Sequence Analysis: the 70% Hurdle," Genome Research, 2000, vol. 10 (4), pp. 398-400. |
Brantley M.A., Jr., et al., "Association of Complement Factor H and LOC387715 Genotypes with Response of Exudative Age-Related Macular Degeneration to Intravitreal Bevacizumab," Ophthalmology, 2007, vol. 114 (12), pp. 2168-2173. |
Brattain M.G., et al., "Heterogeneity of Malignant Cells from a Human Colonic Carcinoma," Cancer Research, 1981, vol. 41 (5), pp. 1751-1756. |
Braun A.H., et al., "New Systemic Frontline Treatment for Metastatic Colorectal Carcinoma," Cancer, 2004, vol. 100 (8), pp. 1558-1577. |
Brawer et al. (1998) "Measurement of complexed PSA improves specificity for early detection of prostate cancer," Urology, 52(3):372-378. |
Brenner S.E., et al., "Errors in Genome Annotation," Trends in Genetics, 1999, vol. 15 (4), pp. 132-133. |
Brogan I.J., et al., "Novel Polymorphisms in the Promoter and 5′ Utr Regions of the Human Vascular Endothelial Growth Factor Gene," Human Immunology, 1999, vol. 60 (12), pp. 1245-1249. |
Brown L.F., et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) by Epidermal Keratinocytes During Wound Healing," Experimental Medicine, 1992, vol. 176 (5), pp. 1375-1379. |
Brown L.F., et al., "Increased Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) In Bullous Pemphigoid, Dermatitis Herpetiformis, and Erythema Multiforme," Journal of Investigative Dermatology, 1995, vol. 104 (5), pp. 744-749. |
Budman et al. (2008) "Biomarkers for detection and surveillance of bladder cancer," CUAJ, 2(3):212-221. |
Capizzi R.L., et al., "Curative Chemotherapy tor Acute Myeloid Leukemia: the Development of High-Dose Ara-C from the Laboratory to Bedside," Investigational New Drugs, 1996, vol. 14 (3), pp. 249-256. |
Carpenter J.F., et al., "Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice," Pharmaceutical research, 1997, vol. 14 (8), pp. 969-975. |
Center for Drug Evaluation and Research Medical Review, Application No. 125418Orig1s000, Jul. 3, 2012, 190 pages. |
Cersosimo et al. (Dec. 1, 1998) "Irinotecan: A New Antineoplastic Agent for the Management of Colorectal Cancer", Annals of Pharmacotherapy, vol. 32, Issue 12, pp. 1324-1333. |
Chiron et al. (Mar. 31, 2014) "Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer," Mol Cancer. Ther. 13(6):1636-1644. |
Chu Q.S., "Aflibercept (AVE0005): An Alternative Strategy for Inhibiting Tumour Angiogenesis by Vascular Endothelial Growth Factors," Expert Opinion Bioinformatics Theraphy, 2009, vol. 9 (2), pp. 263-271. |
Chung M., et al., "Treatment of Malignant Ascites," Current Treatment Options in Oncology, 2008, vol. 9 (2-3), pp. 215-233. |
CN1968709A is in Chinese for which WO2006/009809 is believed to be the English language equivalent. |
Commission Implementing Decision of Jan. 2, 2013 granting marketing authorization under Regulation (EC) No. 726/2004 of the European Parliament and of the Council for "ZALTRAP-aflibercept", European Commission, 45 Pages. |
Cooper M.E., et al., "Increased Renal Expression of Vascular Endothelial Growth Factor (VEGF) and Its Receptor VEGFR-2 in Experimental Diabetes," Diabetes, 1999, vol. 48 (11), pp. 2229-2239. |
Corbett T..H., et al., "Evaluation of Single Agents and Combinations of Chemotherapeutic Agents in Mouse Colon Carcinomas," Cancer, 1977, vol. 40 (5 suppl), pp. 2660-2680. |
Cunningham et al. (Aug. 2001) "Optimizing the Use of Irinotecan in Colorectal Cancer", The Oncologist, vol. 6, Supplement 4, pp. 17-23. |
Cunningham S.A., et al., "Identification of the Extracellular Domains of Flt-1 That Mediate Ligand Interactions," Biochemical and Biophysical Research Communications, 1997, vol. 231 (3), pp. 596-599. |
Dassoulas K., et al., "Common Polymorphisms in the Vascular Endothelial Growth Factor Gene and Colorectal Cancer Development, Prognosis, and Survival," Molecular Carcinogenesis, 2009, vol. 48 (6), pp. 563-569. |
Daugherty A.L., et al., "Formulation and Delivery Issues for Monoclonal Antibody Therapeutics," Advanced drug delivery reviews, 2006, vol. 58 (5-6), pp. 686-706. |
Davis-Smyth T., et al., "Mapping the Charged Residues in the Second Immunoglobulin-Like Domain of the Vascular Endothelial Growth Factor/Placenta Growth Factor Receptor Flt-1 Required for Binding and Structural Stability," The Journal of Biological Chemistry, 1998, vol. 273 (6), pp. 3216-3222. |
Davis-Smyth T., et al., "The Second Immunoglobulin-Like Domain of the Vegf Tyrosine Kinase Receptor Flt-1 Determines Ligand Binding and May Initiate a Signal Transduction Cascade," The Embo Journal, 1996, vol. 15 (18), pp. 4919-4927. |
De Gramont A., et al., "Randomized Trial Comparing Monthly Low-Dose Leucovorin and Fluorouracil Bolus with Bimonthly High-Dose Leucovorin and Fluorouracil Bolus Plus Continuous Infusion for Advanced Colorectal Cancer: A French Intergroup Study", Journal of Clinical Oncology, 1997, vol. 15 (2), pp. 808-815. |
De Groot et al. (2011) "Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept," Clin. Cancer Res. 17(14):4872-4881. |
De Vries C., et al., "The Fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," Science, 1992, vol. 255 (5047), pp. 989-991. |
DE19724793A1 is in German. An English translation of the abstract is attached. |
DE19841985A1 is in German. An English translation of the abstract is attached. |
Declaration of Dr. Sarah Hymowitz submitted to the European Patent Office on Oct. 5, 2009, by Genentech, Inc. during prosecution of European Patent Appl. No. 05023819.5. |
Delaration of Dr. Olin Gavin Thurston given in EP04779050.6 , 2010. |
DeLisser H.M., et al., "Molecular and Functional Aspects of PECAM-1/CD31," Immunology Today, 1994, vol. 15 (10), pp. 490-495. |
DeMolis P., et al., "Zaltrap. Assessment Report," European Medicines Agency, 2012, pp. 1-91. |
Detmar M., et al., "Increased Microvascular Density and Enhanced Leukocyte Rolling and Adhesion in the Skin of VEGF Transgenic Mice," Investigative Dermatology, 1998, vol. 111 (1), pp. 1-6. |
Detmar M., et al., "Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and Its Receptors in Psoriasis," Experimental Medicine:, 1994, vol. 180 (3), pp. 1141-1146. |
DeVriese A.S., et al., "Antibodies against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experimental Diabetes," American Society of Nephrology, 2001, vol. 12 (5), pp. 993-1000. |
Doerks T., et al., "Protein Annotation: Detective Work for Function Prediction," Trends in Genetics, 1998, vol. 14 (6), pp. 248-250. |
Dowlati et al. (Mar. 2008) "Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study", Clinical Cancer Research, vol. 14, Issue 5, pp. 1407-1412. |
Duncan R., et al., "Polymer Conjugates. Pharmacokinetic Considerations for Design and Development," Clinical Pharmacokinetics, 1994, vol. 27 (4), pp. 290-306. |
Dvorak H.F., et al., "Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis," American Journal of Pathology, 1995, vol. 146 (5), pp. 1029-1039. |
EC SP014068 is in Spanish for which US2004/023864 A1 is believed to be the English-language equivalent. |
EC SP099404 is in Spanish, a copy cannot be located, U.S. Pat. No. 7,919,593 is believed to be the English-language equivalent. |
EC SP1110748 is in Spanish, a copy cannot be located, US2011/150903 is believed to be the English-language equivalent. |
Emmanouilides et al. (2007) "Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study," Biomed Central Cancer. 7:1-7. |
Eremina V., et al., "Glomerular-Specific Alterations of VEGF-A Expression Lead to Distinct Congenital and Acquired Renal Diseases," Clinical Investigation, 2003, vol. 111 (5), pp. 707-706. |
Feron O., et al., "Targeting the Tumor Vascular Compartment to Improve Conventional Cancer Therapy," Trends in Pharmacological Sciences, 2004, vol. 25 (10), pp. 536-542. |
Ferrara N., "VEGF and the quest for tumor angiogenesis factors," Nature Review Cancer, 2002, vol. 2, pp. 795-803. |
Ferrara N., et al., "Discovery and Development of Bevacizumab, an Anti-VEGF Antibody for Treating Cancer," Nature Reviews Drug Discovery, 2004, vol. 8, pp. 391-400. |
Ferrara N., et al., "The Biology of VEGF and Its Receptors," Nature Medicine, 2003, vol. 9 (6), pp. 669-676. |
Ferte et al. (2009) "Wound healing delay after central venous access following DCF/VEGF-trap therapy," Invest New Drugs, 27:583-585. |
Flyvbjerg A., et al., "Amelioration of Long-Term Renal Changes in Obese Type 2 Diabetic Mice by a Neutralizing Vascular Endothelial Growth Factor Antibody," Diabetes, 2002, vol. 51 (10), pp. 3090-3094. |
Formica V., et al., "Predictive Value of VEGF Gene Polymorphisms for Metastatic Colorectal Cancer Patients Receiving First-Line Treatment Including Fluorouracil, Irinotecan, and Bevacizumab," International Journal of Colorectal Disease, 2011, vol. 26 (2), pp. 143-151. |
Formica V., et al., "VEGF Polymorphisms as Predictors of Bevacizumab Efficacy in Metastatic Colorectal Cancer," European Journal of Cancer, 2009, vol. 7 (4), pp. 17. |
FR2462908 is in French for which U.S. Pat. No. 4,353,887 is believed to be the English-language equivalent. |
Fraser H.M., et al., "Single Injections of Vascular Endothelial Growth Factor Trap Block Ovulation in the Macaque and Produce a Prolonged, Dose-Related Suppression of Ovarian Function," Clinical Endocrinology & Metabolism, 2005, vol. 90 (2), pp. 1114-1122. |
Fuh G., et al., "Requirements for Binding and Signaling of the Kinase Domain Receptor for Vascular Endothelial Growth Factor," The Journal of Biological Chemistry, 1998, vol. 273 (18), pp. 11197-11204. |
Gaya A., et al., "A Preclinical and Clinical Review of Aflibercept for the Management of Cancer," Cancer Treatment Reviews, 2012, vol. 38 (5), pp. 484-493. |
Gerber H.P., et al., "Complete Inhibition of Rhabdomyosarcoma Xenograft Growth and Neovascularization Requires Blockade of Both Tumor and Host Vascular Endothelial Growth Factor," Cancer Research, 2000, vol. 60 (22), pp. 6253-6258. |
Glade-Bender J., et al., "Vegf Blocking Therapy in the Treatment of Cancer," Expert Opinion on Biological Therapy, 2003, vol. 3 (2), pp. 263-276. |
Gotlieb W.H., et al., "Intravenous Aflibercept for Treatment of Recurrent Symptomatic Malignant Ascites in Patients with Advanced Ovarian Cancer: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study," The Lancet, Oncology, 2012, vol. 13 (2), pp. 154-162. |
Hank's solution formulation, Retrieved from the Internet. |
Hayashi H., et al., "Biomarkers of Reactive Resistance and Early Disease Progression during Chemotherapy plus Bevacizumab Treatment for Colorectal Carcinoma," Oncotarget, 2014, vol. 5 (9), pp. 2588-2595. |
Heidaran M.A., et al., "Beta Pdgfr-Igg Chimera Demonstrates That Human Beta Pdgfr Ig-Like Domains 1 to 3 are Sufficient for High Affinity Pdgf Bb Binding," Faseb Journal, 1995, vol. 9 (1), pp. 140-145. |
Heidaran M.A., et al., "Chimeric Alpha- and Beta-Platelet-Derived Growth Factor (Pdgf) Receptors Define Three Immunoglobin-Like Domains of the Alpha-Pdgf Receptor That Determine Pdgf-Aa Binding Specificity," The Journal of Biological Chemistry, 1990, vol. 265 (31), pp. 18741-18744. |
Herley M.T., et al., "Characterization of the Vegf Binding Site on the Flt-1 Receptor," Biochemical and Biophysical Research Communications, 1999, vol. 262 (3), pp. 731-738. |
Hileman R.E., et al. , "Glycosaminoglycan-protein Interactions: Definitions of Consensus Sites in Glycosaminoglycan Binding Proteins," BioEssays, 1998, vol. 20, pp. 156-167. |
Hoff P.M., et al., "A Phase I Study of Escalating Doses of the Tyrosine Kinase Inhibitor Semaxanib (Su5416) in Combination with Irinotecan in Patients with Advanced Colorectal Carcinoma," Japanese Journal of Clinical Oncology, 2006, vol. 36 (2), pp. 100-103. |
Holash J., et al., "VEGF-Trap: a VEGF Blocker with Potent Antitumor Effects," Proceedings of the National Academy of Sciences, 2002, vol. 99 (17), pp. 11393-11398. |
Horn et al. (Oct. 13, 2009) "Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501", Journal of Clinical Oncology, vol. 27, No. 35, pp. 6006-6011. |
Hu L., et al., "Vascular Endothelial Growth Factor Trap Combined With Paclitaxel Strikingly Inhibits Tumor and Ascites, Prolonging Survival in a Human Ovarian Cancer Model," Clinical Cancer Research, 2005, vol. 11 (19 Pt 1), pp. 6966-6971. |
Hu L., et al.,"Vascular Endothelial Growth Factor Immunoneutralization Plus Paclitaxel Markedly Reduces Tumor Burden and Ascites in Athymic Mouse Model of Ovarian Cancer," American Journal of Pathology, 2002, vol. 161 (5), pp. 1917-1924. |
Huang J., et al., "Regression of Established Tumors and Metastases by Potent Vascular Endothelial Growth Factor Blockade," Proceedings of the National Academy of Sciences of the United States of America, 2003, vol. 100 (13), pp. 7785-7790. |
Hunt T.K, "Disorders of Wound Healing," World Journal of Surgery, 1980, vol. 4 (3), pp. 271-277. |
Hurwitz H., et al., "Bevacizumab Plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer," The New England Journal of Medicine, 2004, vol. 350 (23), pp. 2335-2342. |
Hwang J., "Irinotecan and 5-FU/Leucovorin in Metastatic Colorectal Cancer: Balancing Efficacy, Toxicity, and Logistics" Cancer Network, 2004, pp. 1-12. |
Ikehata F., et al., "Autoantibodies Against CD38 (ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase) That Impair Glucose-Induced Insulin Secretion in Noninsulin-Dependent Diabetes Patients," Clinical Investigation, 1998, vol. 102 (2), pp. 395-401. |
International Search Report and Written Opinion for Application No. PCT/EP2012/053026, dated Aug. 10, 2012, 22 pages. |
International Search Report and Written Opinion for Application No. PCT/EP2012/057542, dated Jun. 19, 2012, 12 pages. |
International Search Report and Written Opinion for Application No. PCT/EP2013/066299, dated Oct. 30, 2013, 13 pages. |
International Search Report and Written Opinion for Application No. PCT/FR2005/003005, dated May 3, 2006, 10 pages. |
International Search Report and Written Opinion for Application No. PCT/FR2008/000943, dated Feb. 18, 2009, 9 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/EP2017/051363, dated May 19, 2017, 16 Pages. |
International Search Report for Application No. PCT/CN2013/085764, dated Apr. 3, 2014, 7 pages. |
International Search Report for Application No. PCT/EP2013/064079, dated Sep. 25, 2013, 3 pages. |
International Search Report for Application No. PCT/EP2014/072731, dated Feb. 13, 2015, 3 pages. |
International Search Report for Application No. PCT/EP2015/066262, dated Aug. 24, 2015, 4 pages. |
International Search Report for Application No. PCT/US2000/014142, dated Nov. 23, 2000, 4 pages. |
International Search Report for Application No. PCT/US2002/02466, dated Apr. 24, 2002, 2 pages. |
International Search Report for Application No. PCT/US2004/009246, dated Nov. 4, 2004, 3 pages. |
International Search Report for Application No. PCT/US2004/017721, dated Feb. 21, 2005, 3 pages. |
International Search Report for Application No. PCT/US2004/023815, dated Feb. 15, 2005, 6 Pages. |
International Search Report for Application No. PCT/US2004/21059, dated Jul. 7, 2005, 4 pages. |
International Search Report for Application No. PCT/US2005/020762, dated Feb. 13, 2006, 4 Pages. |
International Search Report for Application No. PCT/US2006/004557, dated Sep. 19, 2006, 5 Pages. |
International Search Report for Application No. PCT/US2006/010600, dated Sep. 19, 2006, 3 pages. |
Internet articles, VEGF trap in treating patients with solid tumors or non-hodgkin's lymphoma online, XP002305401, Retrieved from the Internet. |
Invitrogen Corporation (Aug. 11, 2008) "Technical Resources-Media Formulations: Hank's Balanced Salt Solution (HBSS) (1X) liquid", 1 Page. |
Irinotecan, Merck Index 15th Edition (2013). |
Isambert N., et al., "Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors," Clinical Cancer Research, 2012, vol. 18 (6), pp. 1743-1750. |
Jain R.K., et al., "Biomarkers of Response and Resistance to Antiangiogenic Therapy," Nature Reviews Clinical Oncology, 2009, vol. 6 (6), pp. 327-338. |
Jain R.K., et al., "Lessons from Phase III clinical trials on anti-VEGF therapy for cancer," Nature Clinical Practice Oncology, 2006, vol. 3 (1), pp. 24-40. |
Jain R.K., et al., "The Role of Vascular Endothelial Growth Factor SNPs as Predictive and Prognostic Markers for Major Solid Tumors," Molecular cancer therapeutics, 2009, vol. 8 (9), pp. 2496-2508. |
Jensen-Pippo K.E., et al., "Enteral Bioavailability of Human Granulocyte Colony Stimulating Factor Conjugated with Poly(Ethylene Glycol)," Pharmaceutical Research, 1996, vol. 13 (1), pp. 102-107. |
Ji, H. et al., "Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin as first-line Therapy for Advanced Colorectal Cancer," Jpn. J. Clin. Oncol. 35(4):214-217 (2005). |
Jin K., et al., "Aflibercept (VEGF Trap): One More Double-Edged Sword of Anti-VEGF Therapy for Cancer?," Clinical and Translational Oncology, 2010, vol. 12 (8), pp. 526-532. |
Jones-Bolin S., et al., "The Effects of the Oral, Pan-Vegf-R Kinase Inhibitor Cep-7055 and Chemotherapy in Orthotopic Models of Glioblastoma and Colon Carcinoma in Mice," Molecular Cancer Therapeutics, 2006, vol. 5 (7), pp. 1744-1753. |
Joulain F. et al., "Afilbercept versus placebo in combination with FOLFIRI in previously treated metastatic colorectal cancer (mCRC): Mean overall survival (OS) estimation from is phase III trial (VELOUR)," Journal of Clinical Oncology, vol. 30 Suppl. Abstract 3602, 2012. |
JP2003-501089 is in Japanese for which U.S. Pat. No. 6,833,349 is believed to be the English-language equivalent. |
JP2007-500131 is in Japanese for which U.S. Pat. No. 7,354,579 is believed to be the English-language equivalent. |
JP2008-521866 is in Japanese for which U.S. Pat. No. 8,388,963 is believed to be the English-language equivalent. |
JP2010-532335 is in Japanese for which US2010/0160233 is believed to be the English language equivalent. |
JP6019790 is in Japanese for which U.S. Pat. No. 4,604,463 is believed to be the English-language equivalent. |
Juppner H., et al., "Functional Properties of the Pth/Pthrp Receptor," Bone, 1995, vol. 17 (2 suppl), pp. 39S-42S. |
Kabbinavar F., et el., "Phase Ii, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (Fu)/Leucovorin (Lv) with Fu/Lv Alone in Patients with Metastatic Colorectal Cancer," Journal of Clinical Oncology, 2003, vol. 21 (1), pp. 60-65. |
Kaklamani V.G., et al., "Role of Capecitabine (Xeloda) in Breast Cancer," Expert Review Sat Anticancer Therapy, 2003, vol. 3 (2), pp. 137-144. |
Katayama D.S., et al., "Retrospective Statistical Analysis of Lyophilized Protein Formulations of Progenipoietin Using PLS: Determination of the Critical Parameters for Long-term Storage Stability," Journal of Pharmaceutical Sciences, 2004, vol. 93 (10), pp. 2609-2623. |
Kaufman R.M., et al., "Transgenic Analysis of a 100-Kb Human Beta-Globin Cluster-Containing DNA Fragment Propagated as a Bacterial Artificial Chromosome," Blood, 1999, vol. 94 (9), pp. 3178-3184. |
Kendall R.L., et al., "Identification of a Natural Soluble form of the Vascular Endothelial Growth Factor Receptor, Flt-1, and its Heterodimerization with Kdr," Biochemical and Biophysical Research Communications, 1996, vol. 226 (2), pp. 324-328. |
Kendall R.L., et al., "Inhibition of Vascular Endothelial Cell Growth Factor Activity by an Endogenously Encoded Soluble Receptor," Proceedings of the National Academy of Sciences of the United States of America, 1993, vol. 90 (22), pp. 10705-10709. |
Keyomarsi K., et al., "Folinic Acid Augmentation of the Effects of Fluoropyrimidines on Murine and Human Leukemic Cells," Cancer Research, 1986, vol. 46 (10), pp. 5229-5235. |
Keyt B.A., et al., "Identification of Vascular Endothelial Growth Factor Determinants for Binding Kdr and Flt-1 Receptors. Generation of Receptor-Selective Vegf Variants by Site-Directed Mutagenesis," The Journal of Biological Chemistry, 1996, vol. 271 (10), pp. 5638-5646. |
Kim E.S., et al., "Potent Vegf Blockade Causes Regression of Coopted Vessels in a Model of Neuroblastoma," Proceedings of the National Academy of Sciences of the United States of America, 2002, vol. 99 (17), pp. 11399-11404. |
Konner J., et al., "Use of Soluble Recombinant Decoy Receptor Vascular Endothelial Growth Factor Trap (VEGF Trap) to Inhibit Vascular Endothelial Growth Factor Activity," Clinical Colorectal Cancer, 2004, vol. 4 (2), pp. S81-S85. |
Konner J., et al., "Use of Soluble Recombinant Decoy Receptor Vascular Endothelial Growth Factor Trap (VEGF Trap) to Inhibit Vascular Endothelial Growth Factor Activity," Clinical Colorectal Cancer, vol. 4, Suppl. 2, 2004, pp. S81-S85. |
Kopetz S., et al., "Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance," Journal of Clinical Oncology, 2010, vol. 28 (3), pp. 453-459. |
Kurnianda J., et al., "Elevation of Vascular Endothelial Growth Factor in Indonesian Advanced Stage Nasopharyngeal Carcinoma," Kobe Journal of Medical Sciences, 2009, vol. 55 (2), pp. E36-E44. |
Lambrechts D. et al., "Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting," British Journal of Cancer, vol. 113, No. 7, 2015, pp. 1027-1034. |
Liu et al. (2013) "Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab," Cancer Medicine, 2(2):234-242. |
Lockhart A.C., et al., "Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients with Advanced Solid Tumors," Journal of Clinical Oncology, 2010, vol. 28 (2), pp. 207-214. |
Loupakis F., et al., "6115 VEGF Gene Polymorphisms in the Prediction of Benefit from First-Line FOLEFIRI Plus Bevacizumab (BV) in Metastatic Colorectal Cancer (mCRC) Patients (pts)," European Journal of Cancer, 2009, vol. 7 (2), p. 357. |
Ludwig et al. (2005) "Biomarkers in cancer staging, prognosis and treatment selection," Nature Reviews, 5:845-855. |
Mahadevan D., et al., "Structural Role of Extracellular Domain 1 of Alpha-Platelet-Derived Growth Factor (Pdgf) Receptor for Pdgf-Aa and Pdgf-Bb Binding," The Journal of Biological Chemistry, 1995, vol. 270 (46), pp. 27595-27600. |
Maitland M.L., et al., "Vascular Endothelial Growth Factor Pathway," Pharmacogenet Genomics, 2010, vol. 20 (5), pp. 346-349. |
Mallone R., et al., "Anti-CD38 Autoantibodies in Type? Diabetes," Diabetes/Metabolism Research and Reviews, 2006, vol. 22 (4), pp. 284-294. |
Mallone R., et al., "Autoantibody Response to CD38 in Caucasian Patients with Type 1 and Type 2 Diabetes," Diabetes, 2001, vol. 50 (4), pp. 752-762. |
Mantovani et al. (1994) "Folate Binding Protein Distribution in Normal Tissues and Biological Fluids From Ovarian Carcinoma Patients as Detected by the Monoclonal Antibodies MOv18 and MOv19," European Journal of Cancer, 30A (3):363-369. |
Maung K., et al., "Capecitabine/Bevacizumab Compared to Capecitabine Alone in Pretreated Metastatic Breast Cancer: Results of a Phase III Study)," Clinical Breast Cancer, 2003, vol. 3 (6), pp. 375-377. |
Mayer L.D., et al., "Ratiometric Dosing of Anticancer Drug Combinations: Controlling Drug Ratios After Systemic Administration Regulates Therapeutic Activity in Tumor-Bearing Mice." Molecular Cancer Therapeutics, 2006, vol. 5 (7), pp. 1854-1863. |
Mettlin et al. (1994) "Relative Sensitivity and Specificity of Serum Prostate Specific Antigen (PSA) Level Compared with Age-Referenced PSA, PSA Density and PSA Change," Cancer, 74(5):1615-1620. |
Mi Y., et al., "Effects of Polyethylene Glycol Molecular Weight and Concentration on Lactate Dehydrogenase Activity in Solution and After Freeze-Thawing," PDA Journal of Pharmaceutical Science and Technology, 2002, vol. 56 (3), pp. 115-123. |
Morton, Control of hypertension induced by anti-VEGF trap therapy with anti--hypertensive drugs, Regeneron Pharmaceuticals, Inc., document filed during examination of EP06720549.2, Additional Data pp. 1-14, 2014. |
Ngo J.T., et al., Computational complexity, protein structure prediction, and the Levinthal paradox, In Merz and Le Grand (Eds.) Birkhauser; Boston, 1994, pp. 491-495. |
Nickloff B.J. "The Immunologic and Genetic Basis of Psoriasis," Archives of Dermatology, 1999, vol. 135 (9), pp. 1104-1110. |
Nickoloff B.J., et al., "Injection of Pre-Psoriatic Skin with CD4+ T Cells Induces Psoriasis," American Journal of Pathology, 1999, vol. 155 (1), pp. 145-158. |
Palu G., et al., "In Pursuit of New Developments for Gene Therapy of Human Diseases," Journal of Biotechnology, 1999, vol. 68 (1), pp. 1-13. |
Park J.E., et al., "Placenta Growth Factor. Potentiation of Vascular Endothelial Growth Factor Bioactivity, in Vitro and in Vivo, and High Affinity Binding to Flt-1 But Not to Flk-1/Kdr," The Journal of Biological Chemistry, 1994, vol. 269 (41), pp. 25646-25654. |
Pasqualetti G., et al., "Vascular Endothelial Growth Factor Pharmacogenetics: A New Perspective for Anti-Angiogenic Therapy," Pharmacogenomics, 2007, vol. 8 (1), pp. 49-66. |
Pepe et al. (2001) "Phase of Biomarker Development for Early Detection of Cancer," Journal of the National Cancer Institute, 93(14):1054-1061. |
Pettit D.K., et al., "The Development of Site-Specific Drug-Delivery Systems for Protein and Peptide Biopharmaceuticals," Trends in Biotechnology, 1998, vol. 16 (8), pp. 343-349. |
Phillips A.J., et al., "The Challenge of Gene Therapy and DNA Delivery," The Journal of Pharmacy and Phamacology, 2001, vol. 53 (9), pp. 1169-1174. |
Poon R.T., et al., "Clinical Implications of Circulating Angiogenic Factors in Cancer Patients," Journal of Clinical Oncology, 2001, vol. 19 (4), pp. 1207-1225. |
Reagan-Shaw et al. (Mar. 2008) "Dose Translation from Animal to Human Studies Revisited", FASEB Journal, vol. 22, No. 3, pp. 659-661. |
Reinacher-Schick A. et al., "Drug Insight antiangiogenic therapies for gastrointestinal cancers—focus on monoclonal antibodies" Nature 5(5): 250-263 (2008). |
Rixe et al. A phase I dose escalation (DE) and pharmacokinetics (PK) study of intravenous afilbercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2 in patients with advanced solid tumors. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).vol. 26,No. 15S (May 20 Supplement), 2008:3557. * |
Rixe et al., Journal of Clinical Oncology, 2006 (Jun. 20 supplement), vol. 24: Abstract #13161. |
Rudge J.S., et al., "VEGF Trap Complex Formation Measures Production Rates of VEGF, Providing a Biomarker for Predicting Efficacious Angiogenic Blockade," Proceedings of the National Academy of Sciences, 2007, vol. 104 (47), pp. 18363-18370. |
Rudikoff et al. (1982) "Single amino acid substitution altering antigen-binding specificity," Proc. NAtl. Acad. Sci. USA, 79:1979-1983. |
Saltz et al. (Sep. 28, 2000) "Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer", The New England Journal of Medicine, vol. 343, pp. 905-914. |
Saltz L., "Irinotecan-Based Combinations for the Adjuvant Treatment of Stage III Colon Cancer," Oncology, 2000, vol. 14 (12), pp. 47-50. |
Sanofi (Jul. 26, 2012) "Aflibercept Versus Placebo in Combination with Irinotecan and 5-FU in the Treatment of Patients with Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen (VELOUR)", ClinicalTrials.gov Identifier: NCT00561470, 4 Pages. |
Sanofi (Nov. 20, 2007), "Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen (VELOUR)", pp. 6. |
Sanofi-Regeneron (Jun. 5, 2012), Clincal Trial of Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen (VELOUR), 25 pp. |
Schneider B.P., et al., "Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms with Outcome in a Trial of Paclitaxel Compared with Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: Egog 2100," Journal of Clinical Oncology, 2008, vol. 26 (28), pp. 4672-4678. |
Semela D., et al., "Angiogenesis and Hepatocellular Carcinoma," Journal of Hepatology, 2004, vol. 41 (5), pp. 864-880. |
Sharifi J., et al., "Improving Monoclonal Antibody Pharmacokinetics via Chemical Modification," The Quarterly Journal of Nuclear Medicine, 1998, vol. 42 (4), pp. 242-249. |
Shibuya M., et al., "Nucleotide Sequence and Expression of a Novel Human Receptor-Type Tyrosine Kinase Gene (Flt) Closely Related to the Fms Family," Oncogene, 1990, vol. 5 (4), pp. 519-524. |
Skolnick J., et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era," Trends in Biotechnology, 2000, vol. 18 (1), pp. 34-39. |
Smerdel M.P., et al., "The Predictive Value of Serum Vegf in Multiresistant Ovarian Cancer Patients Treated with Bevacizumab," Gynecologic Oncology, 2010, vol. 118 (2), pp. 167-171. |
Smith T.F., et al., "The Challenges of Genome Sequence Annotation or "The Devil is in the Details"," Nature Biotechoology, 1997, vol. 15 (12), pp. 1222-1223. |
Stewart M.W., et al., "Clinical and Differential Utility of VEGF Inhibitors in Wet Age-Related Macular Degeneration: Focus on Aflibercept," Clinical Ophthalmology , 2012, vol. 6, pp. 1175-1186. |
Stone R.L., et al., "Collateral Damage: Toxic Effects of Targeted Antiangiogenic Therapies in Ovarian Cancer," The Lancet, Oncology, 2010, vol. 11 (5), pp. 465-475. |
Suri C., et al., "Increased Vascularization in Mice Overexpressing Angiopoietin-1," Science, 1998, vol. 282 (5388), pp. 468-471. |
Tabernero et al. (2011) "Results from VELOUR,a phase 3 study of aflibercept (a) versus placebo (pbo) in combination with FOLFIRI for the treatment of patients with previsouly treated metastatic colorectal cancer (mCRC)," Eur J. Cancer, 47(Suppl2): p. 5, abstract 6LBA, Sep. 2011. |
Tanaka et al., Characterization of the Ligand Binding Domain of FKT-1, The 8th Annual Meeting of Japanese Molecular Biology, Nov. 21, 1995, Abstract 2P-227. |
Tanaka K., et al., "Characterization of the Extracellular Domain in Vascular Endothelial Growth Factor Receptor-1 (Flt-1 Tyrosine Kinase)," Japanese Journal of Cancer Research, 1997, vol. 88 (9), pp. 867-876. |
Tang P.A., et al., "Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients With Previously Treated Metastatic Colorectal Cancer," Clinical Cancer Research, 2012, vol. 18 (21), pp. 6023-6031. |
Tang R, et al., "Abstract 4027, Phase II Thal of Aflibercept (VEGF Trap) in Previously Treated Patients with Metastatic Colorectal Cancer (MCRC): A PMH Phase II Consortium Trial," Journal of Clinical Oncology, 2008, vol. 26 (15S). |
Tate C.G., et al., "Comparison of Seven Different Heterologous Protein Expression Systems for the Production of the Serotonin Transporter," Biochimica et Biophysica Acta, 2003, vol. 1610 (1), pp. 141-153. |
Teng L.S., et al., "Clinical Applications of VEGF-Trap (Aflibercept) in Cancer Treatment," Chinese Medical Association, 2010, vol. 73 (9), pp. 449-456. |
Terman B.I., et al., "Identification of a New Endothelial Cell Growth Factor Receptor Tyrosine Kinase," Oncogene, 1991, vol. 6 (9), pp. 1677-1683. |
Terman B.I., et al., "Identification of the Kdr Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor," Biochemical and Biophysical Research Communications, 1992, vol. 187 (3), pp. 1579-1586. |
Tew W.P., et al., "Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors," Clinical Cancer Research, 2010, vol. 16 (1), pp. 358-366. |
Thomas., et al., Clinical Experience with Aflibercept in Metastatic Colorectal Cancer ,mCRC, A Single Institution Experience, NCRI Cancer Conference, Abstract LB82, 2013. |
Tiilikainen A., et al., "Psoriasis and HLA-Cw6," British Journal of Dermatology, 1980, vol. 102 (2), pp. 179-184. |
Tischer et al., "The Human Gene for Vascular Endothelial Growth Factor Multiple Protein forms are Encoded through Iternative Exeon Splicing," Journal of Biological Chemistry, 1991, vol. 266 (18), pp. 11947-11954. |
Tokuriki N., et al., "Stability Effects of Mutations and Protein Evolvability," Current Opinion in Structural Biology, 2009, vol. 19 (5), pp. 596-604. |
Tournigand C., et al., "Folfiri Followed by Folfox6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized Gercor Study," Journal of Clinical Oncology, 2004, vol. 22 (2), pp. 229-237. |
Tsutsumi Y., et al., "Pegylation of Interleukin-6 Effectively Increases its Thrombopoietic Potency,"Thrombosis and Haemostasis, 1997, vol. 77 (1), pp. 168-173. |
U.S. Appl. No. 11/293,761, filed Dec. 2, 2005, Antitumor Combinations Containing a VEGF-Inhibiting Agent and 5FU, 2006-0178305. |
U.S. Appl. No. 12/508,834, filed Jul. 24, 2009, Antitumor Combinations Containing a VEGF-Inhibiting Agent and 5FU or a Derivative Thereof, U.S. Pat. No. 8,388,963. |
U.S. Appl. No. 12/651,767, filed Jan. 4, 2010, Antitumour Combinations Containing a VEGF Inhibiting Agent and Irinotecan, 2010-0160233. |
U.S. Appl. No. 13/783,919, filed Mar. 4, 2013, Antitumor Combinations Containing a VEGF-Inhibiting Agent and 5FU or a Derivative Thereof, 2013-0184205. |
U.S. Appl. No. 14/000,942, filed Aug. 22, 2013, Single Nucleotide Polymorphisms in the Promoter of VEGFA Gene and Their Use as Predictive Markers for Anti-VEGF Treatments, 2013-0330341. |
U.S. Appl. No. 14/153,795, filed Jan. 13, 2014, Antitumour Combinations Containing a VEGF Inhibiting Agent and Irinotecan, 2014-0127202. |
U.S. Appl. No. 14/611,561, filed Feb. 2, 2015, Article of Manufacture Comprising Aflibercept or ZIV-Aflibercept, 2015-0216795. |
U.S. Appl. No. 15/408,827, Submitted Jan. 18, 2017, Method for Predicting the Outcome of a Treatment With Aflibercept of a Patient Suspected to Suffer From a Cancer. |
U.S. Appl. No. 15/414,722, Submitted Jan. 25, 2017, Method for Predicting the Outcome of a Treatment With Aflibercept of a Patient Suspected to Suffer From a Cancer by Measuring the Level of a Plasma Biomarker. |
US National Institutes of Health: A study of Intravenous Aflibercept with Docetaxel in Chinese Patients with Solid Tumors, [retrieved on Jan. 13, 2015-], Retrieved from the Internet. |
Van Cutesm E., et al., "Addition of Aflibercept to Fluorouacil, Leucovorin, and Irinotecan Improves Survival in a Phase Iii Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen," Journal of Clinical Oncology, 2012, vol. 30 (28), pp. 3499-3506. |
Van Cutsem E. et al., "Intravenous (IV) Aflibercept versus Placebo in Combination with Irinotecan/5-FU (Folfiri) for Second-Line Treatment of Metastatic Colorectal Cancer (MCRC): Results of a Multinational Phase III Trial (EFC10262-Velour)," Annals of Oncology, 2011, vol. 22 Suppl. 5, Abstract O-0024. |
Van Cutsem E., et al., "Cetuxintab Plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status," Journal of Clinical Oncology, 2011, vol. 29 (15), pp. 2011-2019. |
VanHoefer U., et al., "Irinotecan in combination with new agents," European Journal of Cancer Supplements, 2004 vol. 2 (7), pp. 14-20. |
Verslype et al Validation of the selected dsoe of afilbercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin in a phase I clinical trial of patients (pts) with advanced solid tumros (STs): preliminary results.Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). vol. 26, No. 15S, 2008:14540. * |
Vredenburgh J.J., et al., "Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma," Clinical Cancer Research, 2007, vol. 13 (4), pp. 1253-1259. |
Wang A., et al., "Rapid Analysis of Gene Expression (Rage) Facilitates Universal Expression Profiling," Nucleic Acids Research, 1999, vol. 27 (23), pp. 4609-4618. |
Wang et al. (2012) "Aflibercept in the treatment of metastatic colorectal cancer," Clin. Med. Insights: Oncology. 6:19-30. |
Wang W., "Instability, Stabilization, and Formulation of Liquid Protein Pharmaceuticals," International Journal of Pharmaceutics, 1999, vol. 185 (2), pp. 129-188. |
Warner T.G. "Enhancing Therapeutic Glycoprotein Production in Chinese Hamster Ovary Cells by Metabolic Engineering Endogenous Gene Control with Antisense DNA and Gene Targeting," Glycobiology, 1999, vol. 9 (9), pp. 841-850. |
Webb S.D., et al., "A New Mechanism for Decreasing Aggregation of Recombinant Human Interferon-gamma by a Surfactant: Slowed Dissolution of Lyophilized Formulations in a Solution Containing 0.03% Polysorbate 20," Journal of Pharmaceutical Sciences, 2002, vol. 91 (2), pp. 543-558. |
Wehland M. et al., "Biomarkers for Anti-Angiogenic Therapy in Cancer," International Journal of Molecular Sciences, vol. 14, No. 5, 2012, pp. 9338-9364. |
Wells J.A., et al., "Additivity of Mutational Effects in Proteins," Biochemistry, 1990, vol. 29 (37), pp. 8509-8517. |
Wiesmann C., et al., "Crystal Structure at 1.7 a Resolution of Vegf in Complex with Domain 2 of the Flt-1 Receptor," Cell, 1997, vol. 91 (5), pp. 695-704. |
Wigley P., et al., "Site-Specific Transgene Insertion: An Approach," Reproduction, Fertility, and Development, 1994, vol. 6 (5), pp. 585-588. |
Witmer A.N., et al., "Vascular Endothelial Growth Factors and Angiogenesis in Eye Disease," Progress in Retinal and Eye Research, 2003, vol. 22 (1), pp. 1-29. |
WO2006/059012 A1 is in French for which US2006/0178305 is believed to be the English language equivalent. |
WO2009/024667 A2 is in French for which US2010/0160233 is believed to be the English language equivalent. |
WO99/13909 is in Japanese with an English-language abstract. U.S. Appl. No. 09/508,420 is believed to be the English-language equivalent; and. |
Wong A.K., et al., "Excessive Tumor-Elaborated VEGF and Its Neutralization Define a Lethal Paraneoplastic Syndrome," Proceedings of the National Academy of Sciences, 2001, vol. 98 (13), pp. 7481-7486. |
Wormald M.R., et al., "Glycoproteins: Glycan Presentation and Protein-Fold Stability," Structure, 1999, vol. 7 (7), pp. R155-R160. |
Written Opinion for Application No. PCT/US2006/010600, dated Sep. 25, 2007, 4 pages. |
Wrone-Smith T., et al., "Dermal Injection of Immunocytes Induces Psoriasis," Journal of Clinical Investigation, 1996, vol. 98 (8), pp. 1878-1887. |
Wulff C., et al., "Prevention of Thecal Angiogenesis, Antral Follicular Growth, and Ovulation in the Primate by Treatment with Vascular Endothelial Growth Factor Trap R1R2," Endocrinology, 2002, vol. 143 (7), pp. 2797-2807. |
Yamazaki., et al., , "Phase I Dose Escalation and Pharmacokinetics Study of Intravenous Aflibercept Plus Irinotecan 5-Fluorouracil, and Folinic Acid Folfiri in Patients With Metastatic Colorectal Cancer," Journal of Clinical Oncology, 2011, vol. 29 (4), pp. 538. |
Yang et al. is in Chinese with an English-language abstract. |
Yang et al., Progress in the treatment of colorectal cancer, Oncology Progress, vol. 5, No. 2, pp. 143-150 (2007). |
Yang J.C., et al., "The Use of Polyethylene Glycol-Modified Interleukin-2 (Peg-II-2) in the Treatment of Patients with Metastatic Renal Cell Carcinoma and Melanoma. a Phase I Study and a Randomized Prospective Study Comparing II-2 Alone Versus II-2 Combined with Peg-II-2," Cancer, 1995, vol. 76 (4), pp. 687-694. |
Yazici Y.D., et al., "Antivascular Therapy of Oral Tongue Squamous Cell Carcinoma with Ptk787," The Laryngoscope, 2005, vol. 115 (12), pp. 2249-2255. |
Yokoi K., et al., "Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model," Cancer Research, 2005, vol. 65 (9), pp. 3716-3725. |
Yu J.C., et al., "Differential Requirement of a Motif Within the Carboxyl-Terminal Domain of Alpha-Platelet-Derived Growth Factor (Alpha Pdgf) Receptor for Pdgf Focus Forming Activity Chemotaxis, or Growth," The Journal of Biological Chemistry, 1995, vol. 270 (13), pp. 7033-7036. |
Yu J.C., et al., "Structural Coincidence of Alpha Pdgfr Epitopes Binding to Platelet-Derived Growth Factor-Aa and a Potent Neutralizing Monoclonal Antibody," The Journal of Biological Chemistry, 1994, vol. 269 (14), pp. 10668-10674. |
Zaltrap Marketing Authorization as issued by the European Commission ,2013. |
Zehetner et al. (May 21, 2015) "Systemic Counterregulatory Response of Placental Growth Factor Levels to Intravitreal Aflibercept Therapy," Invest. Opthamol. Visual Sci. 56(5):3279-3286. |
Zimmermann G.R., et al., "Multi-Target Therapeutics: When the Whole is Greater than the Sum of the Parts," Drug Discovery Today 2007, vol. 12 (1-2), pp. 34-42. |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11033606B2 (en) | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) | |
Sun et al. | Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma | |
Van Cutsem et al. | Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen | |
Diel et al. | The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease | |
Halle et al. | Defining and targeting BRAF mutations in solid tumors | |
WO2014006113A1 (en) | Method of treating cancer by effective amounts of aflibercept | |
Pfeiffer et al. | Current role of antibody therapy in patients with metastatic colorectal cancer | |
Bardia et al. | TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2–breast cancer | |
Giaccone et al. | A placebo-controlled phase ii study of ruxolitinib in combination with pemetrexed and cisplatin for first-line treatment of patients with advanced nonsquamous non–small-cell lung cancer and systemic inflammation | |
Ji et al. | A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01) | |
Cerbone et al. | Combination therapy in metastatic renal cell carcinoma: Back to the future? | |
Levy et al. | Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane‐based induction chemotherapy in locally advanced head and neck cancer | |
Wang et al. | Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma | |
Wang et al. | Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816 | |
Torregrosa et al. | FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study | |
Sideras et al. | North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane | |
Rodriguez-Vida et al. | Avelumab for the treatment of urothelial cancer | |
Bylicki et al. | Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study | |
Racadot et al. | Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010–02) | |
OA16640A (en) | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI). | |
NZ617573B2 (en) | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) | |
TW202133887A (en) | Combination therapy with liv1-adc and pd-1 antagonist | |
Guerrero-Ramos et al. | Multidisciplinary consensus document on the current treatment of bacille Calmette-Guérin-unresponsive non-muscle invasive bladder tumor | |
Kainickal et al. | Targeted therapy in recurrent or metastatic head and neck carcinoma | |
Hu et al. | Trop2-targeted therapy in breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANOFI, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CASTAN, REMI;REEL/FRAME:043970/0297 Effective date: 20120713 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: SANOFI, FRANCE Free format text: CHANGE OF ADDRESS;ASSIGNOR:SANOFI;REEL/FRAME:068105/0767 Effective date: 20240416 |